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INTRODUCTION
             Pharmaceutical  analysis deals not only with medicaments (drugs and
formulations), but also with their precursors i.e. with the raw material whose degree
of purity, which in turn decides the quality of medicaments. The quality of a drug is
determined, after establishing its authenticity, which is carried by testing its purity and
the quality of the pure substance in the drug and its formulations.
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC):
            High-performance liquid chromatography is a chromatographic technique
used to separate the components in a mixture,  to identify each component,  and to
quantify each component .The method involves a liquid sample being passed over a
solid adsorbent material packed into a column using a flow of liquid solvent. Each
analyte in the sample interacts slightly differently with the adsorbent material, thus
retarding the flow of the analytes. If the interaction is weak, and the analytes flow off
the column in a short amount of time, and if the interaction is strong, then the elution
time is long.
           Chromatography may be defined as a method of separating a mixture of
components into individual components through equilibrium distribution between two
phases. (Sharma B.K.1994) 
        The HPLC method was considered the choice of estimation, since this method is
the most powerful of all chromatographic and other separative methods. The HPLC
method has enabled analytical chemist to attain great success in solving his analytical
problems. The HPLC is the method of choice in the field of analytical  chemistry,
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since this method is  specific,  robust,  linear,  precise,  and accurate and the limit  of
detection is low and also it offers the following advantages.
The  schematic  representation  of  an  HPLC  instrument  typically  includes  a
sampler,  pumps,  and  a  detector.  The  sampler  brings  the  sample  mixture  into  the
mobile phase stream which carries it into the column. The pumps deliver the desired
flow and composition of the mobile phase through the column. The detector generates
a signal proportional to the amount of sample component emerging from the column,
hence   allowing  for  quantitative  analysis  of  the  sample  components  .A digital
microprocessor  and user software  control  the HPLC instrument  and provide data
analysis. Some models of mechanical pumps in a HPLC instrument can mix multiple
solvents together in ratios changing in time, generating a composition gradient in the
mobile phase. Various detectors are in common use, such as UV/Vis, photodiode array
(PDA) or Refractive index (RI).
SCHEMATIC REPRESENTATION OF HPLC SYSTEM
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COMPONENTS OF HPLC SYSTEM:
Pump
Pump generates a flow of elute from the solvent reservoir to the system. Most
pumps used in current LC system generate the flow by back-and forth motion of a
motor  –driven  piston.  (Reciprocating  pumps).  Because  of  this  piston  motion,  it
produces  “pulses”.  There  have  been  large  system  improvements  to  reduce  this
pulsation and the recent pumps create much less pulse compared to the older ones.
Recent analysis requires very high sensitivity to quantify a small amount of analytes,
and thus even a minor change in the flow rate can influence the analysis. Therefore,
the pumps required for the high sensitivity analysis needs to be highly precise. 
Injector
            An injector is placed next to the pump. The simplest method is to use a
syringe, and the sample is introduced to the flow of eluent. Since the precision of LC
measurement is largely affected by the reproducibility of sample injection, the design
of injector is an important factor. The most widely used injection method is based on
sampling loops. The use of auto sampler (auto-injector) system is also widely used
that allows repeated injections in a set scheduled-timing.
Column
           The separation is performed inside the column; therefore, it can be said that the
column is the heart of an LC system. The packing material generally used is silica or
polymer  gels.  The  eluent  used  for  LC varies  from acidic  to  basic  solvents.  Most
column housing is made of stainless steel, since stainless is tolerant towards a large
variety of solvents. However, for the analysis of some analytes such as biomolecules
and ionic compounds, contact with metals is not desired, thus polyether ether ketone
(PEEK) column housing is used instead.
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Detector
Separation of analytes is performed inside the column, Whereas a detector is used
to observe the obtained separation .The composition of the eluent is consistent when
no analyte is present .While the presence of analyte changes the composition of the
eluent.  What  detector  does  is  to  measure  these  differences.  This  difference  is
monitored as a form of electronic signal.
On-line detectors
 Refractive index 
 UV/Vis Fixed wave length 
 UV/Vis variable  wave length 
 UV/Vis Diode array
  Fluorescence
 Conductivity
  Mass –Spectrometric (LC/MS)
 Evaporative light scattering
Off-line detector
• FTIR spiral disk monitor requires sample transfer on the germanium disk and
following scanning in FTIR instrument.
Recorder
The change in eluent detected by a detector is in the form of electronic signal,
and thus it is still not visible to our eyes. Nowadays, computer based data processor
(integrator) is more common .There are software that are specifically designed for LC
system. It provides not only data acquisition, but features like peak-fitting, base line
correction, automatic concentration calculation, molecular weight determination, etc.
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Degasser
The eluent used for LC analysis may contain gases such as oxygen that are
non-visible to our eyes. When gas is present in the eluent, this is detected as a noise
and causes unstable baseline. Generally used method includes sparging (bubbling of
inert gas), use of aspirator, distillation system, and/or heating and stirring. However,
the method is not convenient and also when the solvent is left for a certain time period
(e.g.,  during  the  long  analysis),  gas  will  dissolve  back  gradually.  Degasser  uses
special polymers membrane tubing to remove gases. The numerous very small pores
on the surface of the polymer tube allow the air to go through while preventing any
liquid to go though the pore. By placing this tubing under low pressure container, it
created pressure differences inside and outside the tubing (higher inside the tubing).
This difference let the dissolved gas to move through the pores and remove the gas.
Compared to classical batch type degassing, the degasser can be used on-line; it is
more convenient and efficient. 
Column heater
The LC separation is often largely influenced by the column temperature. Also
for some analysis, such as sugar and organic acid, better resolutions can be obtained at
elevated temperature (50~80oC). It  is also important  to keep stable temperature to
obtained repeatable results even it is analyzed at around room temperature. There are
possibilities that small different of temperature causes different separation results. The
columns are generally kept inside the column oven (column heater). 
(Willard et.al, 1988). 
Dept.of Pharmaceutical Analysis                5       JKKMMRF College of Pharmacy
Chapter – 1                                                                                                  Introduction
INTRODUCTION TO HPLC METHOD DEVELOPMENT
Method development has following steps:
Collect information on sample, define separation goals
Need for special HPLC procedure, sample pretreatment, etc.
Choose detector and detector settings
Choose LC method, preliminary run, select best separation conditions
Optimize separation conditions
Check for problems
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Recover purified material
Validate method for release to routine laboratory
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A  good  method  development  strategy  should  require  only  as  many
experimental runs as are necessary to achieve the desired final result. Finally method
development  should  be  as  simple  as  possible,  and  it  should  allow  the  use  of
sophisticated tools such as computer modeling. 
The  important  factors,  which  are  to  be  taken  into  account  to  obtain  reliable
quantitative analysis, are:
1. Careful sampling and sample preparation.
2. Appropriate choice of the column.
3. Choice of the operating conditions to obtain the adequate resolution of the
mixture.
4. Reliable performance of the recording and data handling systems.
5. Suitable integration/peak height measurement technique.
6. The mode of calculation best suited for the purpose.
7. Validation of the development method.
(Synder et.al 1983). 
Careful sampling and sample preparation
Before beginning method development, it is need to review what is known 
about the sample in order to define the goals of separation. The sample related 
information that is important is summarized in below. 
Number of compounds present 
Chemical structure
Molecular weight of compounds
pka Values of compounds
UV spectra of compounds
Concentration range of compounds in samples of interest
Sample solubility
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The  chemical  composition  of  the  sample  can  provide  valuable  clues  for  the  best
choice of initial conditions for an HPLC separation.
Separation Goals
The goals of HPLC separation need to be specified clearly, which include:
• The  use  of  HPLC  to  isolate  purified  sample  components  for  spectral
identification or quantitative analysis.
• It may be necessary to separate all degradants or impurities from a product for
reliable content assay.
• In quantitative analysis, the required levels of accuracy and precision should be
known (a precision of + 1 to 2% is usually achievable).
• Whether a signal HPLC procedure is sufficient for a raw material or one or
more different procedure are desired for formulations.
• When the number of samples for analysis at one time is greater than 10, a run 
time less than 20 minutes often will be important.    
Sample preparation 
Sample come in various forms:
• Solution ready for injection.
• Solutions that require dilution, buffering, addition of and internal standard 
or other volumetric manipulation.
•  Solids must be dissolved or extracted.
• Samples that require pretreatment to remove interference and /or protect the
column or equipment from damage.
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             Most samples for HPLC analysis require weighing and /or volumetric dilution
before injection. Best results are often obtained when the composition of the sample
solvents is close to that of the mobile phase since this minimizes baseline upset and
other  problems.  Some samples  require  a  partial  separation  (pretreatment)  prior  to
HPLC,  because  of  need  to  remove  interference,  concentrate  sample  analyte  or
eliminate “column killers”. 
             The samples may be of two types, regular or special. The regular samples are
typical  mixtures  of  small  molecules  (<2000Da)  that  can  be  separated  by  normal
starting conditions. Whereas special samples are better separated under customized
conditions given below.
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 Sample Requirements
Inorganic ions
Isomers
Enantiomers
Biological
Macromolecules
Detection is primary problem; use ion 
chromatography.
Some isomers can be separated by reserved-phase 
HPLC and are then classified as regular samples; 
better separations of isomers are obtained using 
either ( 1)normal – phase HPLC or(2) reversed –
phase separations with cyclodextrin-silica columns.
These compounds require “chiral” conditions for 
their separation.
Several factors make samples of this kind “special”, 
molecular conformation, polar functionality, and a 
wide range of hydrophobicity.
“Big” molecules require column packing with large 
pores (>>10-nm diameters); in addition, biological 
molecules require special conditions as noted above.
Choice of the column
            The separation of the column in HPLC is somewhat similar to the selection of
columns  in  G.C,  in  the  sense  that,  in  the  adsorption  and  partition  modes,  the
separation mechanism is  based on inductive  forces,  dipole-dipole interactions  and
hydrogen bond formation. In case of ion-exchange chromatography, the separation is
based  on  the  differences  in  the  charge,  size  of  the  ions  generated  by the  sample
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molecules and the nature of ionisable group on the stationary phase. In case of size –
exclusion  chromatography the  selection  of  the  column is  based  on  the  molecular
weight and size of the sample components. Selection of columns based on the method
is briefly summarized in below.
Method /Description /Columns Preferred Method
Reversed – Phase HPLC
Uses water- organic mobile phase
 Columns: C18 (ODS), C8, Phenyl, 
trimethylsilyl (TMS), and cyano.
Iron –pair HPLC
Uses water – organic mobile phase, a 
buffer to control pH, and an ion –pair 
reagent
Columns:  C18 , C8, Cyano
Normal-phase HPLC
Uses mixtures of organic solvents as 
mobile phase. Columns:  cyano, diol, 
amino, silica
First choice for most samples, especially 
neutral or non-ionized compounds that 
dissolve in water-organic mixtures
Acceptable choice for ionic or ionisable 
compounds, especially bases or cations.
Good second choice when reserved-phase
or ion-pair HPLC is ineffective; first 
choice for lipophilic samples that do not 
dissolve well in water-organic mixtures; 
first choice for mixtures of isomers and 
for preparative HPLC
Operating conditions to obtain the adequate resolution of the mixture
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             Most of the drug come under the category of regular samples mean typical
mixtures  of  small  molecules  (<2000Da)  that  can  be separated using more or  less
standardized starting conditions. Regular samples can be further classified as neutral
or ionic. Samples classified as ionic include acids, bases, amphoteric compounds and
organic salts. If the sample is neutral, buffers or additives are generally not required in
the mobile phase.
         Acids or bases usually require the addition of a buffer to the mobile phase. For
basic or cationic samples, less acidic reserve phase columns are recommended. Based
on recommendations of the conditions, the first exploratory run is carried and then
improved  systematically.  On  the  basis  of  the  initial  exploratory  run  isocratic  or
gradient elution can be selected as most suitable. If typical reverse-phase conditions
provided inadequate sample retention, it suggests the use of either ion-pair or normal
Phase HPLC. Alternatively, the sample may be strongly retained with 100% ACN as
mobile phase suggesting the use of non-aqueous reverse phase chromatography or
normal phase HPLC.  
Method Development 
        One approach is to use an isocratic mobile phase of some average organic
solvent strength (50%). A better alternative is to use a very strong mobile phase first
(80 -100%) then reduce % B as necessary. The initial separation with 100% B results
in rapid elution of the entire sample, but few groups will separate. Decreasing the
solvent strength shows the rapid separation of all components with a much longer run
time, with a broadening of latter bands and reduced retention sensitivity. Goals that
are to be achieved in method development are briefly summarized in below.
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Goal Comment
Resolution
Separation time
Quantization
Pressure
Peak height 
Solvent
consumption 
Precise and rugged quantitative analysis requires that Rs be 
greater than 1.5.
< 5 – 10 min is desirable for routine procedures.
≤ 2% for assay; ≤5% for less-demanding analyses.
≤15% for trace analyses.
<150 bar is desirable, <200 bar is usually essential (new 
column assumed).
Narrow peaks are desirable for large signal/noise rations.
Minimum mobile – phase use per run is desirable.
Separation or resolution is a primary requirement in quantitative HPLC .The
resolution (Rs)  value  should be maximum (Rs  > 1.5)  favors  maximum precision.
Resolution usually degrades during the life of the column and can vary from day to
day with minor fluctuations in separation conditions. Therefore, values of Rs =2 or
greater should be the goal during method development for sample mixtures.  Such
resolution will favor both improved assay precision and grater method ruggedness. 
               Some HPLC assays do not require base line separation of the compounds of
interest  (qualitative  analysis).In  such  case  only  enough  separation  of  individual
components  is  required  to  provide  characteristic  retention  times  for  peak
identification.
  The time required for a separation (runtime = retention time for base band)
should be as short  as possible and the total  time spent on method development is
reasonable (runtimes 5 to 10 minutes are desirable).
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             Condition for the final HPLC method should be selected so that the operating
pressure with a new column does not exceed 170 bar (2500psi) and upper pressure
limit below 2000 psi is desirable. There are two reasons for this pressure limit, despite
the fact that most HPLC equipment can be operated at much higher pressures. First,
during the life of a column, the backpressure may rise by a factor of as much as due to
the gradual plugging of the column by particulate matter. Second,  at lower pressure
(<170 bars) pumps, sample valves and especially auto samplers operate much better,
seals  last  longer,  columns tend  to  plug less  and  system reliability is  significantly
improved.  For these reasons,  a  target  pressure of  less than 50% of the maximum
capability of the pump is desirable, when dealing with more challenging samples or if
the  goals  of  separation  are  particularly  stringent,  a  large  number  of  method
development runs may be required to achieve acceptable separation.
(Skoog et.al, 2009) 
Repeatable separation 
As the experimental runs described above are being carried out, it is important
to  confirm that  each  chromatogram can be repeated.  When we change conditions
(mobile phase, column, and temperature) between method development experiments,
enough time must elapse for the column to come into with the new mobile phase and
temperature.  Usually  column  equilibration  is  achieved  after  passage  of  10  to  20
volumes  of  the  new mobile  phase  through  the  column.  However;  this  should  be
confirmed by repeating the experiment under the same conditions.  When constant
retention times are observed in two such back – to- back repeat experiments (+ 0.5%
or better), it can be assumed that the column is equilibrated and the experiments are
repeatable. 
Optimization of HPLC method 
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During the optimization stage, the initial sets of conditions that have evolved
from  the  first  stages  of  development  are  improved  or  maximized  in  terms  of
resolution and peak shape,  plate   counts  asymmetry,  capacity factor,  elution time,
detection  limits,  limit  of  quantitation  and  overall  ability  to  quantify  the  specific
analyte  of  interest.  Optimization  of  a  method  can  follow  either  of  two  general
approaches:
 Manual
 Computer driven
The manual approach involves varying one experimental variable at a time, while
holding all other constant  and recording changes in response.  The variables might
include  flow rate,  mobile  or  stationary phase  composition,  temperature,  detection
wavelength and pH. This approach to system is slow, time consuming and potentially
expensive. However, it may provide a much better understanding of the principles and
theory involved and of interactions of the variables. 
         In the second approach, computer driven automated method development,
efficiency is optimized while experimental input is minimized. This approach reduce
the time, energy and cost of all instrumental method development.
The various parameters that include to be optimized during method development are 
A. Selection of mode of separation.
B. Selection of stationary phase.
C. Selection of mobile phase.
D. Selection of detector.
Selection of mode of separation 
In reverse phase mode, the mobile phase is comparatively more polar than the
stationary phase. For the separation of polar or moderately polar compounds, the most
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preferred mode is reverse phase. The nature of the analyte is the primary factor in the
selection of the mode of separation. A second factor is the nature of the matrix. 
Selection of stationary phase
             Selection of the column is the first and the most important step in method
development. The appropriate choice of separation column indicates three different
approaches.
 Selection of separation
 The particle size and nature of the column packing
 The physical parameters of the column i.e. the length and the diameter some
of  the  important  parameters  considered  while  selecting  chromatographic
columns are
 Length and diameter of the column
 Packing material
 Shape of the particles
 Size of the  particles
 % of carbon loading
 Pore volume
 Surface area 
 Reproducibility and reliability
 End capping
In this case, the column selected had a particle size of 5µm and an internal diameter of
4.6mm.The  column  is  selected  depending  on  the  nature  of  the  solute  and  the
information about the analyte. Reversed phase mode of chromatography facilities a
wide range of columns like dimethyl silane (C2), butysilane (C4), octylsilane (C8), 
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Octadecyslane (C18), base deactivated silane (C18), BDS phenyl, Cyanopropyl (CN),
nitro, amino etc. silica based columns with different cross linking’s in the increasing
order of polarity are as follows: 
<………………..Non-polar………….moderately polar…………..polar……..>
                             C18 < C8 < C6 < Phenyl < Amino < Cyano < Silica
           C18  was chosen for this study since it is most retentive one. The sample
manipulation  becomes  easier  with  this  type  of  column.  Generally  longer  columns
provide better separation due to higher the theoretical plate numbers. Columns with
5µm particle size give the best compromise of efficiency.
      Peak shape is equally important in method development. Columns that provide
symmetrical peaks are always preferred while peaks with poor asymmetry can result
in,
• Inaccurate plate number and resolution measurement
• Imprecise quantitation
• Degraded and undetected minor bands in the peaks tail
• Poor retention reproducibility
                 A useful and practical measurement of peak shape is peak asymmetry factor
and peak tailing factor. Peak asymmetry is measured at 10% of full peak height and
peak tailing factor at 5%. Reproducibility of retention times and capacity factor is
important for developing a rugged and repeatable method. 
           A column which gives separation of all the impurities and degradants from
each other and from analyte peak and which is rugged for variation in mobile phase
shall be selected.
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Selection of mobile phase
          The primary objective in selection and optimization of mobile phase is to
achieve optimum separation of all the individual impurities and degradants from each
other and from analyte peak.
          In  liquid chromatography, the solute retention is governed by the solute
distribution factor, which reflects the different interactions of the solute – stationary
phase, solute-mobile phase, and mobile phase-stationary phase. For a given stationary
phase, the nature and the composition of which has to be judiciously selected in order
to get appropriate and required solute retention. The mobile phase has to be adapted in
terms  of  elution  strength  (solute  retention)  and  solvent  selectivity  (solute
separation).Solvent polarity is the key word in the chromatographic separations since
a polar mobile phase will give rise to low solute retention in normal phase and high
solute retention in reverse phase LC. The selectivity will be particularly altered if the
buffer pH is close to the pKa of the analytes. The following are the parameters, which
shall be taken into consideration while selecting and optimizing the mobile phase.
 Buffer
 pH of the buffer
 Mobile phase composition
Buffers if any and its strength 
             Buffer and its strength play an important role in deciding the peak symmetries
and separations. Some of the most commonly employed buffers are
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 Phosphate buffers prepared using salts like KH2PO4, K2HPO4, NaH2PO4, and
Na2HPO4
.
 Phosphoric acid buffers prepared using H3PO4.
 Acetate buffers-ammonium acetate, sodium acetate etc.
 Acetic acid buffers prepared using CH2COOH.
            The retention also depends on the molar strengths of the buffer-molar strength
is  increasingly proportional  to  retention  times.  The strength  of  the  buffer  can  be
increasing, if necessary to achieve the required separations. The solvent strength is a
measure of its ability to pull analyte from the column. It is generally controlled by the
concentration  of  the  solvent  with  the  highest  strength.  The  useful  pH  range  for
columns is 2 to 8, since siloxane linkages are cleaved below pH-2 while at pH values
above eight, silica may dissolve.
Mobile phase composition 
             Most chromatographic separations can be achieved by choosing the optimum
mobile  phase  composition.  This  is  due  to  the  fact  that  fairly  large  amount  of
selectively can be achieved by choosing the qualitative and quantitative composition
of  aqueous  and  organic  portions.  Most  widely  used  solvents  in  reverse  phase
chromatography are  methanol  and  Acetonitrile.  Experiments  should  be  conducted
with mobile phases having buffers with different pH and different organic phases to
check for the best separations of analyte peak. A mobile phase which gives separation
of analyte peak 
and which is rugged for variation of both aqueous and organic phase by at least  +
0.2% of the selected mobile phase composition should be used. 
Selection of Detector
Dept.of Pharmaceutical Analysis                19       JKKMMRF College of Pharmacy
Chapter – 1                                                                                                  Introduction
            The detector was chosen depending upon some characteristic property of the
analyte like UV absorbance, florescence, conductance, oxidation, reduction etc. The
characteristics that are to be fulfilled by a detector to be used in HPLC determination
are,
 High sensitivity facilitating trace analysis
 Negligible baseline noise to facilitate lower detection.
 Large linear dynamic range.
 Low dead volume.
 Inexpensive to purchase and operate.
            Pharmaceutical  ingredients do not absorb all  UV light equally,  so that
selection of  detection wavelength is  important.  An understanding of  the UV light
absorptive  properties  of  the  organic  impurities  and  the  active  pharmaceutical
ingredient is very helpful.  For the greatest  sensitivity  max should be used. Ultra
violet wavelengths below 200nm should be avoided because detector noise increases
in this region. Higher wave lengths give greater selectivity. 
Performance calculations
             Carrying out system suitability experiment does the performance calculations.
System suitability experiments can be defined as tests to ensure that the method can
generate results of acceptable accuracy and precision. The requirements for system
suitability are usually developed after method development and validations have been
completed.  The  criteria  selected  will  be  based  on  the  actual  performance  of  the
method as determined during its validation. For example, if sample retention times
form part  of  the  system suitability  criteria,  their  variation  SD can  be  determined
during validation.
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        System suitability might then require that retention times fall within a + 3 SD
range during routine performance of the method.
        The USP (2000) defines parameters that  can be used to determine system
suitability prior  to  analysis  include plate  number(n),tailing factor(T),resolution(Rs)
and  relative  standard  deviation  (RSD)  of  peak  height  or  peak  area  for  respective
injections.
        The RSD of peak height or area of five injections of a standard solution is
normally  accepted  as  one  of  the  standard  criteria  .For  assay  method  of  a  major
component,  the  RSD  should  typically  be  less  than  1%  for  these  five  respective
injections. 
    The plate number and / or tailing factor are used if the run contains only one peak.
For  chromatographic  separations  with  more  than  one  peak,  such  as  an  internal
standard assay or an impurity method expected to contain many peaks, some measure
of separations such as Rs is recommended. Reproducibility of tR   or k value for a
specific compound also defines system performance.
         The column performance can be defined in terms of column plate number. As
the plate count is more the column is more efficient. (Lyoyd.R et.al 1997)
METHOD VALIDATION 
         The word “Validation’’ means “Assessment’’ of validity or action of proving
effectiveness.
Definition
ICH defines validation as “establish the documented evidence which provides a high
 degree of assurance that a specific process will consistently produce a product of
predetermined specifications and quantity attributes.’’
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              Method validation is the process to confirm that the analytical procedure
employed  for  a  specific  test  is  suitable  for  its  intended  use.  Method  need  to  be
validated or revalidated.
 Before their introduction into routine use
 Whenever the conditions change for which the method has been validated,
e.g., instrument with different characteristics
 Whenever the method is changed, and the change is outside the original scope
of the method.
 Purpose of validation
 Enable  the  scientists  to  communication  scientifically  and  effectively  on
technical matter.
 Setting the standards of evaluation procedures for checking compliance and
taking remedial action.
 Economic: Reduction in cost associated with process sampling and testing.
 As quality of the product cannot always be assured by routine quality control
because of testing of statistically insignificant number of samples.
 Retrospective validation is useful for trend comparison of results compliance
to CGMP/CGLP.
 Closure  interaction  with  pharmacopoeial  forum  to  address  analytical
problems.
 International  pharmacopoeial  harmonization  particularly  in  respect  of
impurities determination and their limits.
           Method validation is completed to ensure that an analytical methodology is
accurate, specific, reproducible and rugged over the specified range that an analyte
will be analyzed. Method validation provides an assurance of reliability during normal
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use, and is sometime referred to as “the process of providing documented evidence
that the method does what it is intended to do’’.
For method validation, these specifications are listed in USP chapter <1225>,and can 
be referred to as the “eight steps of method validation”. as shown in figure below.
These terms are referred to as “analytical performance parameters’’. or sometimes as 
“analytical figures of merit.’’ 
In response to this situation, one of the first harmonization projects taken up by the
ICH was the development of a guideline on the “Validation of Analytical Methods”
Definitions and Terminology. “ICH divided the “Validation characteristics” somewhat
differently, as outlined in Figure below
The USP Eight steps of method validation
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ICH Method Validation Parameters
Method validation parameters
 The developed methods were validated by following steps:
A.Accuracy
         It is defined as closeness of agreement between the actual (true) value and mean
analytical  value  obtained  by applying a  test  method  number  of  times.  Spike  and
recovery studies are performed to measure accuracy; a known sample is added to the
excipients and the actual drug value is compared to the value found by the assay.
Accuracy is expressed as the bias or the % error between the observed value and the
true value (assay value/actual value x 100 %.)
          The accuracy is acceptable if the difference between the true value and mean
measured value does  not  exceed the RSD values  obtained for  repeatability of  the
method.  The parameter  provides  information about the recovery of  the drug from
sample  and  effect  of  matrix,  as  recoveries  are  likely  to  be  excessive  as  well  as
deficient.
Procedure:
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Use a minimum of 3 spiking concentrations in the excipients solution. Prepare
two  samples  of  each  concentration.  Test  the  6  samples  in  triplicate  on  one  run.
Measure expected vs. average measured value. Calculate the% recovery.
B.Precision
           The precision of an analytical method is the degree of agreement among
individual test results when the method is applied repeatedly to multiple sampling of
homogenous sample. 
            Precision is the measure of the degree of repeatability of an analytical method
under normal operation and is normally expressed as the percent relative standard
deviation (%RSD) or coefficient  of variation (% CV) for a statistically significant
number of samples. According to the ICH, precision should be performed at three
different levels: repeatability, intermediate precision, and reproducibility. 
Repeatability is the result of the method operating over a short time interval under
the same conditions (or) is the % RSD of multiple determinations of a single sample
in a single test run (intra-assay precision). It should be determined from a minimum of
nine determinations covering the specified range of the procedure (for example, three
levels three repetitions each) or from a minimum of six determinations at 100% of the
test or target concentration.
Procedure:
• Prepare three dilution of the sample (high/medium/low concentrations in the 
range). 
• Test 10 replicates of each dilution of the sample.
• Calculate the average and standard deviation for each point on the curve.
• Calculate the RSD for each point on the curve.
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Intermediate precision is the results from within lab variations due to random events
such as different days, analysts, equipment, etc. In determining intermediate precision,
experimental design should be employed so that the effects (if any) of the 
  individual variables can be monitored (or) intermediate precision (also called inter-
assay precision) measure the % RSD for multiple determinations of a single sample,
controls  and  reagents  analyzed  in  several  assay   runs  in  the  same  laboratory.
Procedure:
• Prepare three dilutions of the sample (high/medium/low concentrations in the
range).
• Test triplicates of each dilution of the sample inn three different assays.
• Do for day- to –day variations
• Do for lot-to- lot variations of assay materials
• Do for technician – to – technician variation.
• Calculate the average and standard deviation for each point on the curve for
each individual test.
• Calculate the RSD for each point on the curve between the assay runs.
Reproducibility refers to the precision between laboratories usually in collaborative
studies  and  not  directly  relevant  to  assay  validation  in  a  manufacturing  facility.
Documentation in support of precision studies should include the standard deviation,
relative standard deviation, coefficient of variation, and the confidence interval.
C.Specificity
              It is the ability of an analytical method to assess unequivocally the analyte of
interest in the presence of components that may be expected to be present, such as
impurities,  degradation  products  and  matrix  components.  It  is  not  possible  to
demonstrate that an analytical procedure is specific for a particular analyte. In such
case a combination of two or more analytical procedure is recommended to achieve
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the necessary level of discrimination. Lack of specificity of an individual analytical
procedure may be compensated by other supporting analytical procedures or tests.
               In case of the assay, demonstration of specificity requires that the procedure
is unaffected by the presence of impurities or excipients. In practice, this can be done
by spiking the drug substances or product with appropriate levels of impurities or
excipients and demonstrating that the assay is unaffected by the presence of these
extraneous materials. If the degradation product impurity standards are unavailable,
specificity may be demonstrated by comparing the test results of samples containing
impurities  or  degradation  products  to  a  second  well-characterized  procedure  e.g.,
pharmacopoeia  method  or  other  validated  analytical  procedure  (independent
procedure). These comparisons should include samples stored under relevant stress
conditions (e.g. light, heat humidity, acid/base hydrolysis, oxidation.ect.)
D.Limit of Detection
             The limit of detection (LOD) is defined as the lowest concentration of an
analyte in a sample that can be detected, not quantitated. It is a limit test that specifies
whether or not an analyte is  above or below a certain value.  It  is  expressed as  a
concentration at a specified signal-to- noise ratio, usually two –or three-to-one. The
ICH  has  recognized  the  signal-to-noise  ratio  convention,  but  also  lists  two  other
options  to  determine  LOD: visual  non-instrumental  methods  and  a  means  of
calculating the LOD. The method used to determine LOD should be documented and
supported, and an appropriate number of samples should be analyzed at the limit to
validate the level.
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Procedure
 Prepare a standard concentration of the product in the appropriate solution.
 Prepare a blank solution without any sample (zero concentration).
 Perform the assay at least 3 times in duplicate according to SOP.
 Measure the amount present in the sample and blank.
 Calculate the average for the sample and blank.
 Calculate and standard deviation of the blank.
 Calculate the LOD as 3.3xSD/slope of linearity curve.        
E.Limit of Quantitation
              The limit of quantitation (LOQ) is defined as the lowest concentration of an
analyte in a sample that can be determined with acceptable precision and accuracy
under  the  stated  operational  conditions  of  the  method.  That  is,  as  the  LOQ
concentration level decreases, the precision increases. If better precision is required, a
higher concentration must be reported for LOQ.
Procedure: 
             The calculation method is again based on the standard deviation of the
response (SD) and the slope of the calibration curve (S)  according t the formula:
LOQ = 10(SD/S). Again, the standard deviation of the response can be determined
based on the standard deviation of the blank, on the residual standard deviation of the
regression line, or the standard deviation of y- intercepts of regression lines. 
F. Linearity:
               It is ability of an assay to obtain test results, which are directly proportional
to the concentration of an analyte in the sample. The determination of linearity will
Identify the range of the analytical assay. It can be measured as slope of the regression
line  and  its  variance  or  as  the  coefficient  of  determination  (R2)  and  correlation
coefficient(R). 
Procedure:
           Determining the coefficient of correlation R for dilutions of the sample over
the range claimed for assay.
1. Prepare 6 to 8 sample dilutions across the claimed range
2. Test each dilution in triplicate for 3 runs
3. Record expected values, actual values, and % recoveries for each run
4. Analyze each set of dilutions as a linear curve and calculate R for each assay.
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Alternative:
              Calculate the accuracy and precisions at each dilution. Range is the highest
and lowest concentration with satisfactory accuracy and precision. If  the validation
study for an analytical test is well planed it should be possible to design the protocol
to consider many of the parameters in a single series of test, for instance selectivity
(specificity) linearity, range, accuracy and precision for a potency test. 
 G. Range:
            Range is the interval between the upper and the lower levels of analyte
(inclusive) that have been demonstrated to be determined with precision, accuracy and
linearity  using  the  method  as  written.  If  the  relationship  between  response  and
concentration is  the linear,  the range may be estimated by means of  a  calibration
curve.
           The range is normally expressed in the same units as the test results obtained
by the method. The ICH guidelines specify a minimum of five concentration levels,
along with certain minimum specified ranges. For assay the minimum specified range
is from 80-120% of the target concentration. For an impurity test, the minimum range
from the reporting level of each impurity, to 120% of the specification.  (For toxic or
more potent impurities, the range should be commensurate with the controlled level). 
H. Ruggedness:
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               Ruggedness, according to the USP, is the degree of reproducibility of the
results obtained under a variety of conditions, expressed as %RSD. The ruggedness of
an analytical method is the degree of reproducibility of test results obtained by the
analysis  of  the  same  samples  under  a  variety  of  conditions  such  as  different
laboratories,  different  analysts,  different  instruments,  different  lot  of  reagents,
different elapsed assay times, different assay temperatures different days, etc. 
I. Robustness:
               ICH defines robustness as a measure of the method’s capability to remain
unaffected by small, but deliberate variations in method parameters. Robustness can
be  partly  assured  by  good  system  suitability  specifications.  The  evaluation  of
robustness should be considered during the development phase and depends on the
type  of  procedure  under  study.  It  should  show the  reliability of  an  analysis  with
respect to deliberate variations in method parameters. If  the results of a method or
other  measurements  are  susceptible  to  variations  in  method  parameters,  these
parameters should be adequately controlled and a precautionary statement included in
the method documentation. One consequence of the evaluation of robustness should
be that a series of system suitability parameters (e.g., resolution test) is established to
ensure that the validity of the analytical procedure is maintained whenever used.
Examples of typical variation are:
• Stability of analytical solutions
• Extraction time
In the case of liquid chromatography, examples of typical variations are 
• Influence of variations of pH in a mobile phase
• Influence of variations in mobile phase composition
• Different columns(different lots and/or suppliers)
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• Temperature
• Flow rate.
In the case of gas-chromatography, examples of typical variations are 
• Different columns(different lots and/or suppliers)
• Temperature
• Flow rate.
J. System Suitability Test 
            System suitability test  is commonly used to verity resolution, column 
efficiency and repeatability of the chromatographic system to ensure its adequacy for 
a particular analysis. According to the United States pharmacopoeia (USP) and the 
International Conference on Harmonization (ICH), SST is an integral part of many 
analytical procedure.
            Primary SST parameters are most important as they indicate system 
specificity, precision and column stability. Other parameter include capacity factor 
(K) and signal to noise ratio(S/N) for impurity peaks.
             The USP chromatography general chapter states “System suitability test are 
an integral part of gas and liquid chromatographic methods. They are used to verify 
that the resolution and reproducibility of the chromatographic system are adequate for
the analysis to be done. The tests are based on the concept that the equipment, 
electronics, analytical operations and samples to be analyzed constitute an integral 
system can be evaluated as such.” (USP 36-NF 31, 621 – Chromatography) 
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INTERPRETASTION OF CHROMATOGRAMS
 
              Figure below represents a typical chromatographic separation of two
substances, 1 and 2, where t1 and t2 are the respective retention times; and h, h/2, and
Wh/2 are the height, the half – height, and the width at half-height, respectively, for
peak1. W1 and W2 are the respective widths of peaks 1 and 2 at the base line. Air
peaks are a feature of gas chromatograms and correspond to the solvent front in liquid
chromatography.
Figure-1
                Chromatography retention times are characteristic of the compounds they
represent but are not unique. Coincidence of retention times of a test and a reference
substance  can  be  used  as  a  feature  in  construction  of  an  identity  profile  but  is
insufficient  on  its  own  to  establish  identity.  Absolute  retention  times  of  a  given
compound vary from one chromatogram to the next.
Relative Retention times:
 Relative retention time is calculated by the equation Rr = t2/t1 
t1 = Retention time of test.
t2 = Retention time of reference substance, determined under identical experimental
conditions on the same column. 
Relative Retention: 
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t
2
 – t
M
To calculate the relative retention (r) = ---------
t1-tM
Where tM is the retention time of the non-retained marker. 
Resolution 
               The resolution R is a function of column efficiency, N and is specified to 
ensure that closely eluting compounds are resolved from each other, to establish the 
general resolving power of the system, and to ensure that internal standards are 
resolved from the drug.
Figure-2
R is determined by the equation:
R=
1
t2t ¿
¿
2¿
¿
     Or
              2(t2-t2)      
R =    ___________
          1.70 (W1, h/2 + W2, h/2)
t2 and t1 are the retention times of the components. 
Dept.of Pharmaceutical Analysis                34       JKKMMRF College of Pharmacy
Chapter – 1                                                                                                  Introduction
 W2 and W1 are the corresponding width at the bases of the peaks obtained by 
extrapolating the relatively straight sides of the peaks to the base line.
W1h/2 and W2h/2 are the corresponding peak width at half-height.
Resolution 
               1.18(tR2 – tR1)     
R =  _______________
             (Wh1 + W h2)
Where, t R2 > tR1
tR2 and tR1 = Retention times or distances along the baseline from the point of 
injection to the perpendiculars dropped from the maxima of two adjacent peak 
Wh1and Wh2 = peak width at half height. 
Theoretical Plates 
               Column efficiency also may be specified as system suitability requirements, 
especially if there is only one park of interest in the chromatograms. The number of 
the theoretical plates, N, is a measure of column efficiency. It is calculated by the 
equation.
N= 16 [t/w] 2 or    N= 5.54 [t/w1/2]2
t = Retention time of the substance.
w = width of the peak at its base, obtained by extrapolating the relatively straight
sides of the peak to the baseline. 
W1/2 = Peak width at half-height.
 Precision:
                Precision a measure of either degree of reproducibility or of repeatability  is
determined by making replicate  injections  of  standard preparation and  calculating
relative standard deviation. Unless otherwise specified in the individual monograph,
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data from five replicate injections of the standard preparation are used to calculate the
relative standard deviations (SR), if the requirement is 2.0% or less; data from six
replicate injections are used if the relative standard deviation requirement is more than
2.0%.
Relative Standard Deviation in percentage.
SR (%) = 
100
X [
x
Xi¿´2
¿
¿
N1
¿
¿
∑
i=1
i=n
¿
√¿
]
x = Arithmetic mean of the set.
xi = An individual measurement in a set of N measurements.
N= Number of individuals values
Tailing Factor (or) Symmetry factor 
               Tailing factor, T, a measure of peak symmetry, is unity for perfectly
symmetrical peaks and its value increases as tailing factor is pronounced (Fig 1). In
some cases  values less  tan unity may be observed. As peak asymmetry increases,
integration and hence precision becomes less reliable.
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Figure-3
Tailing factor, T = 
W 0.05
2 F
W0.05 = Width of peak at 5% height.
F = Distance from the peak maximum to the leading edge of the peak, the distance is
being measured at a point 5% of the peak height from baseline.
Capacity Factor (Mass distribution ratio):
          Capacity factor k’ of a sample component is a measure of the degree which that
component is retained by the column relative to an unretained component 
           Capacity factor is k, = 
(t rt
0
)
t
0
tr – is the elution time of retained component and
t0 – is the elution time of the unretained sample.
Signal to Noise Ratio: 
            S/N = 
2H
H
Where,
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H   =  Height  of  the  peak  corresponding  to  the  component  concerned,  in  the
chromatogram obtained with the  prescribed reference solution, measured from the
maximum of  the  peak  to  the  extrapolated  baseline  of  the  signal  observed  over  a
distance equal to 20 times the width at half-height. 
h  = Range of the background noise in a chromatogram obtained after injection or
application of a blank, observed over a distance equal to 20 times the width at half-
height  of  the  peak  in  the  chromatogram  obtained  with  the  prescribed  reference
solution and, if possible, situated equally around the place where this peak would be
found. 
Figure-4 
Peak to Valley ratio
          The peak-to-valley ratio (p/v) may be employed as  a  system suitability
requirement in a test for related substances when baseline separation between 2 peaks
is not reached 
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P/v = 
H p
H v
Hp = Height above the extrapolated baseline of the minor peak,
Hv =  Height  above  the  extrapolated  baseline  at  the  lowest  point  of  the  curve
separating the minor and major peaks.(ICH 2007)
Figure-5
 System Suitability Parameters and Recommendations:
Parameter Recommendation
Capacity Factor (k’) The peak should be well-resolved from the other peaks and
the void volume, generally k’>2.0
Repeatability RSD, ≤1% for N≥5 is desirable
Relative retention Not essential as long as the resolution is stated 
Resolution Rs of >2 between the peak of interest and the closed eluting
Tailing Factor (T) T of ≤2
Theoretical Plates (N) In general should be > 2000
STATISTICAL PARAMETERS
Linear regression: 
         Once a linear relationship has been shown to have a high probability by the
value of the correlation coefficient  ‘r’,  then the best  straight line through the data
points has to be estimated. This can often be done be done by visual inspection of the
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calibration graph, but in many cases it is far more sensible to evaluate the best straight
line by linear regression (the method of least squares).
The equation of straight line is y = mx + c
Where, y the dependent variable is plotted as result of changing x, the independent
variable. 
To obtain the regression line ‘y on x’ the slope ‘m’ of the line and the intercept ‘c’ on
the y axis are given by the following equation.
m=
x
∑ ¿
¿
y
∑ ¿
¿
x
∑ ¿
¿
N∑ x2¿
N∑ xy¿
¿
and       c=
x
∑ ¿
¿
y
∑ ¿
¿
x
∑ ¿
¿
N∑ x2¿
N∑ y∑ x 2¿
¿
Correlation coefficient:
When the changes in one variable are associated or followed by changes in the order
it is called correlation. To establish whether there is a liner relationship between two
variables x1 and y1, use Pearson’s correlation coefficient r.
r=
x 1
y1
n∑ y12¿}1/2
¿
¿
x12¿¿
n∑ ¿
{¿
n∑ x 1 y 1∑ x 1 y 1
¿
Where n is the number of data points.
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             The value of r must lie between +1 and -1, the nearer it is to +1, the greater
the probability that a define linear relationship exists between the variables x and y,
values  close  to  +1  indicate  positive  correlation  and  values  close  to  -1,  indicate
negative correlation values of ‘r’ that tend towards zero indicate that x and y are not
linearly related (they made be related in a non-linear fashion).
Standard deviation:
               The standard deviation measures the spread f the data about the mean value.
It is commonly used in statics as a measure of precision statics as a measure of 
Precision and is more meaningful than is the average and is expressed mathematically
as. 
x
Xi¿´
¿
¿
N1
¿
¿
∑
i=1
i=n
¿
S=√¿
Where,
S is the standard deviation.
If N is large (50 or more) then of course it is immaterial whether the term in the 
Denomination is N-1 or N
   Σ = sum
X = observed values
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X´
= Mean or arithmetic average = ΣX/N
X - X´  = deviation of a value from the mean 
N = Number of observations
Percentage relative standard deviation
    It  is  also known as  coefficient  of  variation CV. It  is  defined as  the  standard
deviation (S.D) expressed as the percentage of mean.
  CV or % RSD = 
S . D
X´  x 100
Where, S.D = Standard deviation,
               
X´
 = Mean or arthimetic average.
The variance is defined as S2 and is more important in statistics than S itself.
However, the latter is much more commonly used with chemical data. 
Standard Error of mean: 
        Standard error of mean can be defined as the value obtained by division of
standard  deviation  by square  root  of  number  of  observation.  It  is  mathematically
expressed as 
          S.E =
S . D
√n  
Where, n = number of observations.
S.D = Standard Deviation(Riley et.al,2009) 
Data elements required for essay validation:
It  is  not  always  necessary to  evaluate  every analytical  performance parameter,  as
different  test  methods  require  different  validation  schemes.  The  most  common
categories of assays for which validation data should be required are as follows:
i) Quantitation of major components or active ingredients.
ii) Determination of impurities or degradation compounds.
iii) Determination of performance characteristics
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Category – I: Analytical methods for quantitation of major components of bulk drug
substances or active ingredients (including preservatives) in finished pharmaceutical
products.
Category  –  II:  Analytical  methods  for  determination  of  impurities  in  bulk  drug
substances  or  degradation compounds in  finished  pharmaceuticals  products.  These
methods include quantitative essays and limits tests.
Category – III: Analytical methods of determination of performance characteristics
(E.g. dissolution, drug release). 
The type of method and its intended use dictates which parameters are required to be
investigated. They are illustrated in the below.
Data elements required for assay validation
Analytical
Performance
Parameter
Assay
Category-I
Assay category Assay
Category III
Quantitative Limit Test
Accuracy Yes Yes * *
Precision Yes Yes No Yes
Specificity Yes Yes Yes *
LOD No No Yes *
LOQ No Yes No *
Linearity & 
range
Yes Yes No *
Ruggedness Yes Yes Yes *
*may be required, depending on the nature of specific test. 
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 Comparison of Analytical Parameters Required for Assay validation
         
FDA reviewer Guidance USP  General  Chapter
<1225>
ICH Q2A Guidelines
Accuracy Accuracy Accuracy
Precision  Repeatability
Analysis
Precision Precision
Intermediate precision No Intermediate precision
Reproducibility No No
Specificity / selectivity Specificity Specificity
Detection limit Detection limit Detection limit
Quantitation limit Quantitation limit Quantitation limit
Linearity Linearity Linearity
Range Range Range
No Ruggedness No
Robustness Robustness Robustness
System  suitability  sample
solution stability
System suitability System suitability
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LITERATURE REVIEW
1. Development of UV-spectrophotometric method for the quantititation
  Estimation of ofloxacin and ornidazole in cominatined liquid oral dosage form 
(Ganthi.VM. et.al, 2012.)
      The spectrophotometer at medium scanning speed using U.V spectro photometer
119, systronics. The maximum absorbance for ofloxacin and ornidazole were found in
295.6nm and 310.8nm.the linear function of the concentration range of 2 – 10 µg/ml
for ofloxacin and 5 - 25µg/ml for ornidazole. The percentage recoveries for ofloxacin
and ornidazole were found to be the range of 99.58 - 100.69% and 99.86%
101.0% respectively.
2.  Simultaneous  spectrophometric  estimation  of  ofloxacin  and  ornidazole  in
tablet dosage form. (Bhusari k.P et.al, Jan –Mar 2009.)
    The estimation of ofloxacin and ornidazole simultaneously in tablet dosage form. It
is shows absorbance maxima at 294 nm and 317nm in N/2 acetic acid, respectively.
The linearity was obtained in the concentration range of 2 – 10 µg/ml for ofloxacin
and  2  –30µg/ml  for  ornidazole.  The  percentage  recoveries  for  ofloxacin  and
ornidazole  were  found  to  be  the  range  of  100.32  %+ 0.46  and  99.22  + 0.59
respectively.
3.  A  validation  RP-HPLC  method  for  simultaneous  estimation  of  cefixime
trihydrate and ornidazole in tablet dosage forms. (Sudhakar et.al, Dec 2010.)
     The separation and quantification of cefixime trihydrate and ornidazole in tablet
dosage form. The determination was carried  out using phenomenex C18 column  (25
cm x 4.6mm id) as a stationary phase  and mobile phase  is  acetonitrile :  40mM
KH2PO4  in  proportion  of   40:60(v/v)  with   pH  adjusted  to  6  +  0.5  by  using
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triethylamine. The flow rate was 1.0ml/ml and  the eluent  was  monitored at 310nm.
The retention time of cefixime trihydrate and ornidazole were 2.75 + 0.028 min and
6.67  + 0.018.the  coefficient  of  correlation  and  percentage  recoveries  of  cefixime
trihydrate and ornidazole were 0.9986 and 100.01%, 0.9994 and 99.98% respectively.
4. Spectrometric estimation of cefixime and ofloxacin from tablet dosage form.
(Avanija dube et.al, year March 2011.)
    The simultaneous estimation of cefixime and ofloxacin from tablet dosage form.
Method 1 involves formation of simultaneous equation at 304nm (cefixime) and 296
nm (ofloxacin). Method 2 involves formation of absorbance ratio equation at 275(is
absorptive  point)  using  methanol  dilution.  The  linearity  was  observed  in  the
concentration  range  of  4-  20  µg/ml  for  cefixime  and  2-10  µg/ml  for  ofloxacin.
Recovery studies are cefixime 97 + 0.0016 and ofloxacin   102.22 + 08.
5.  Development  of  colorimetric  method  for  the  analysis  of  Pharmaceutical
formulation containing both ofloxacin and cefixime. (Rajnish Kumar et.al, Nov-
Dec 2010.)
    The determination of ofloxacin and cefixime in same pharmaceutical formulation.  
ofloxacin forms an orange coloured product in the presence of ferric chloride solution
in acidic medium and the absorbance of orange colored species formed was measured
at 435nm. linearity concentration range 15 - 75 µg/ml and cefixime forme a product in
the presence of fehling solution. greenish coloured Species formed was measured at
490nm against reagent .the linearity concentration is 5to 40µg/ml. Recovery studies is
ofloxacin 99.71% and cefixime 99.50%
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6.  Development  and  validation  for  the  simultaneous  estimation  of  ofloxacin  and
tinidazole in tablets. (Dharuman .J et.al, April – June 2009.)
    The separation was carried out using a mobile phase consisting of 0.5%v/v triethylamine 
buffer of pH 3.0 and acetonitrile in the ratio of 73: 27.column used was kromasil C8, 5µ.15 
cm x4.6mm id with flow rate of 1.2 ml /min using PDA detection at 303nm. The linear 
concentration range of 10 – 50 µg/ml and 30 -150 µg/ml for the assay of ofloxacin and 
tinidazole respectively. The Retention times of ofloxacin, tinidazole were found to be   2.3 
and 4.1 min.The limit of LOQ for ofloxacin and tinidazole were found to be 10 and 30µg/ml 
respectively. Recovery studies is ofloxacin 100.85% + 1.256 % and tinidazole 99.58% 
+ 0.896. 
7.  Validated  high  performance  thin  layer chromatography method  for simultaneous
estimation of  ofloxacin and ornidazole  in tablet  dosage form. (Ganthimathi .M et.al,
2006.) 
    The method employed silica gel 60GF254 TLC precoated plates as stationary phase and a
mixture N-butanol: ethanol: ammonia (5:5:4%v/v/v) as mobile phase. The plate was scanned
and quantified at 295nm using camag TLC scanner. The RF values of 0.59 + 0.02 and 0.86 +
0.01 for  ofloxacin and ornidazole  respectively .The migration distances  was 0.82cm .The
calculated the peak area was found to be 102.27 + 0.15 and 103.04 +0.21% respectively.
8.  Development  and  validation  of  column  HPLC and  derivative  spectrophotometric
methods for determination of levofloxacin and ornidazole in combined dosage forms.
(Patel SA et.al, Jul-Aug 2008.)
    The separation was carried out using a mobile phase KH2PO4 buffer (pH 6.8) and methanol,
acetonitrile (70 + 15 + 15 v/v/v). column   used was phenomenox C18 250mm x 4.6mm id,
5µ.with flow rate of 1.5 ml/min using PDA detection at 295nm.The both linear concentration
range of 1-10µg/ml.Recovery studies is levofloxacin  101.7% + 0.,23 and  ornidazole 99.23 %
+  1.57%.The  simultaneous  estimation  of  levofloxacin  and  ornidazole  from tablet  dosage
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form. It  is  shows absorbance maximum at 310nm ornidazole and 295nm levofloxacin the
linear concentration range of 2-40µg/ml the both levofloxacin and ornidazole. Mean recovery
was 99.46% + 0.96 and 100.9 % + 0.72.
9. Development and validation of a method for simultaneous estimation of ofloxacin and
ornidazole in different dissolution media. (Patel D.M et.al, Jul 2012.)  
    The estimation of ofloxacin and ornidazole simultaneously in tablet dosage form. It is
shows absorbance maximum at 294nm in 0.1M Hcl for ofloxacin and 287nm in phosphate
buffer pH 6.8 and phosphate buffer pH7.4 .Which ornidazole showed absorption maxima at
277nm  in  0.1M  Hcl  and  at  319nm  in  two  buffers.  The  linearity  was  obtained  in  the
concentration range of 1 – 8 µg/ml for ofloxacin and 4 - 26 µg/ml for ornidazole.
10.  Simultaneous  estimation  of  ornidazole  and  ofloxacin  by  derivative
spectrophotometry method. (Daxina et.al, May 2011.)
    In  first order derivative spectrophotometry wave length selected for quantitation were
310.9nm for ofloxacin and 297.9nm for ornidazole. In observed in the concentration range of
5 – 25 µg/ml  for  ornidazole and 2 – 10 µg/ml for ofloxacin. The percentage recoveries for
ofloxacin .The percentage recoveries for ofloxacin and ornidazole were found to be the range
of 98.06% - 100.14%, and 99.13% - 101.2% respectively.
11.  A  validated  RP  –HPLC  method  for  simultaneous  estimation  of  cefixime  and
ornidazole in tablet dosage forms. (Satish shelke et.al, July 2012.)
    The separation and quantification of cefixime and ornidazole in tablet dosage form. the
determination was carried out using Kromasil 100 C8 3.5µm Column (150mm x 4.6mm id) as
a stationary phase and mobile phase is water(pH 3.1) : acetonitrile in proportion 75:25 and
adjust pH by using orthophosphoric acid. The   flow rate was 1.0ml/min and the eluent was
monitored at 288nm. The retention time of cefixime and ornidazole were 3.34min and 6.1min
respectively.The  coefficient  of  correlation  and  percentage  recoveries  of  cefixime  and
ornidazole were 0.9983 and 99.86% and 0.9981 and 100.28% respectively.
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12.  A validation RP HPLC method for simultaneous estimation of  Nitazoxanide and
ofloxacin in tablet dosage form. (Sharma .S.et.al, Jan – Feb 2011.)
   The estimation of nitazoxanide and ofloxacin in tablet dosage form.The determination was
carried out using H1Q SIL C18 column (250 x 4.6mm id) as a stationary phase and mobile
phase is acetonitrile: methanol: 0.4M citic acid (60: 30: 10 v/v/v) the flow rate was 0.5ml/min
and the eluent  was  monitored at  304nm.The percentage  mean recovery of  ofloxacin  was
found to be 99.93% nitazoxanide was found to be 99.86%.
13. Development and validation of a method for simultaneous estimation of ofloxacin
and  ornidazole  in  different  dissolution  medium.  (Dasharath  M.patel.et.al,  Jul-  Dec
2012.)
   The estimation of ofloxacin and ornidazole simultaneously in tablet dosage form.It shows
absorbance maximum at 294nm in 0.1N Hcl for ofloxacin and ornidazole at 277nm.It shows
absorbance  maximum at  287nm  in  both  phosphate  buffer  for  ofloxacin  and  319nm for
ornidazole  .The linearity  observed was in the concentration range of 1 -8 µg/ml  and 4 -
25µg/ml for ofloxacin and ornidazole respectively. 
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DRUG PROFILE
Generic Name : Ofloxacin
Structure
                                  
Molecular Formula : C18H20FN3O4
IUPAC name : (±)-9-fluoro-2,3-dihydro-3-methyl-10-(4-
methyl-1-       piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-
1,4-
benzoxazine - 6-carboxylic acid.
Molecular weight : 361.368g/mol
Description : A pale yellow or bright yellow, crystalline power
Solubility : Soluble in glacial acetic acid, slightly soluble in
water, dichloromethane and methanol.
pKa : 6.22
Category : Anti bacterial activity
Pharamacokinetic data
Bioavailability : 85%-95%
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Protein binding : 32%
Metabolism : Metabolized via the liver, extract in the Urine
Half life : 8-9hours
Excertion ; kindly(as conjugates and metabolites)
Mechanism of action
Ofloxacin  is  a  broad-spectrum antibiotic  that  is  active  against  both  Gram-
positive and Gram-negative bacteria. If function by inhibiting DNA gyrase, a type II
topoisomerase,  and  topoisomerase  IV,  which  is  an  enzme  necessary  to  separate
replicated DNA, there by inhibiting cell division .The floroquinolones interface with
DNA replication by inhibiting an enzyme called DNA gyrase.
Contra indication:
 Ofloxacin is now considered to be contraindicated for the treatment of certain
sexually transmitted  diseases.  There  is  one contraindication  now found within the
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2008 package insert for floxin. That being that Floxin is to be avoided in patients with
a known hypersensitive to ofloxacin or other quinolone drugs.  Caution in patients
with liver function disorders (e.g., cirrhosis with or without acites). Ofloxcian is also
considered to be contraindicated within the pediatric population, pregnancy, nursing
mothers,  patients  with  psychiatric  illnesses  and  in  patient  with  epilepsy  or  other
seizure disorders.
Interaction:
Interaction increased the risk of cardio toxicity and arrhythmias, anticoagulant
effect, the formation of non- absorbable complexes, as well as increasing the risk of
toxicity.  Concurrent  administration  of  ofloxacin,  with  magnesium  or  aluminum
antacids,  sucralfate  or  product  containing  calcium,  iron  or  zine  may  substainly
decrease the absorption of ofloxacin, resulting in serum and urine levels considerably
lower then desired.(K.D tripathi 2004)
Generic Name                :                           Ornidazole                          
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Structure                       :         
                                  
Molecular Formula         : C7H10Cl  N3O3
IUPAC Name              : 1-chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)
propan-2-ol Molecular weight         : 219.625 g/mol
Description                    : A white to yellowish white crystalline powder
Solubility                     : Soluble in chloroform and in methanol
Pka                               : 2.5 
Category                          : Antiprotozoal
Mechanism of action:
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Ornidazole  is  a  5-nitroimidazole  derivative  active  against  protozoa  and
anaerobic bacteria.  It  is converted to reduction products that interact with DNA to
cause destruction of helical DNA structure and strand leading to a protein synthesis
inhibition and cell death in susceptible organisms. (www.drug bank .com)
Pharmacodynamics:
Absorption: Readily absorbed  (oral  and  intravaginal);  peak  plasma concentrations
after 2 hr (oral), 12 hr (intravaginal).
Distribution: Body tissues and fluids (wide), CSF. Protein-binding: <15%.
Metabolism: Hepatic.
Excretion: Via urine (as conjugates and metabolites), via faeces (small amounts); 12-
14 hr (elimination) 
Indication:Treatment  of  parasitic  infections,  including  amebiasis,  giardiasis,
and Trichomonas  vaginalis;  treatment  of  infections  due  to  susceptible  strains  of
anaerobic bacteria. 
Contra  indication: Hypersensitivity  to  ornidazole  or  to  other  nitroimidazole
derivatives. 
Adverse  reaction:Somnolence,  headache,  nausea,  vomiting,  dizziness,  tremor,
rigidity,  poor  coordination,  seizures,  tiredness,  vertigo,  temporary  loss  of
consciousness  and  signs  of  sensory  or  mixed  peripheral  neuropathy,  Taste
disturbances, abnormal LFTs, skin reactions.
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Drug interaction:Potentiates effect of coumarin-type oral anticoagulants.  Prolongs
the muscle-relaxant effect of vecuronium bromide. See Below for More ornidazole
Drug Interactions.
Combined drug uses:
Ofloxacin and ornidazole can be used in the management of a variety
of  infections  caused  by  bacteria,  fungi,  and  parasites.  They  are  available  in  a
combination pill in some regions for the convenience of patients; the drugs can also
be taken independently. A medical provider may recommend this option to a patient
who appears to be a good candidate for therapy on the basis of diagnosis and history.
It  is not advised for people who react  badly to quinolone antibiotics or who have
known allergies to either drug. One common use of this drug combination is in the
management  of  gastrointestinal  infections  that  cause  diarrhea  and  discomfort,
including  infections  with  amoebae  and  protozoan’s.  Patients  can  also  take  it  for
urinary tract  infections, as well as  fungal infections of the oral cavity and vagina.
Another application for ofloxacin and ornidazole is treatment of respiratory infections
like bronchitis and pneumonia complicated by the presence of aggressive bacteria.
 Courses of therapy may be relatively short in all these cases, typically between three
and five days. Some sexually transmitted infections, like gonorrhea and  Chlamydia,
are also treatable with ofloxacin and ornidazole. The short course of therapy can be
useful  in  the  management  of  such  conditions  as  it  increases  the  chances  that  the
patient will adhere to the therapy, eliminating the infectious organisms. Patients who
complete their courses of drugs are less likely to experience a recurrence or contribute
to the development of drug resistance that could make future infections harder to treat.
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A combination of ofloxacin and ornidazole can also be used to treat Hansen’s disease,
or leprosy. The medications can be used as part of a larger treatment plan that may
include other drugs. They can be very effective in a short period of time, reducing the
amount  of  time  the  patient  needs  to  spend  in  treatment  to  eliminate  the  bacteria
responsible for the disease. 
In addition to benefiting the patient, this helps prevent the spread of the organisms to
the rest of the community. People taking ofloxacin and ornidazole can experience side
effects  like  increased  light  sensitivity  and  gastrointestinal  discomfort.  It  is  also
possible to have severe side effects like rashes and difficulty breathing, which indicate
an  allergic reaction to one or both medications. If these develop, the patient should
discuss them with a medical provider to determine the next step, like switching to a
different drug to treat the infection. 
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AIM AND PLAN WORK
  For the simultaneous estimation of drugs present in dosage forms UV- spectrophotometer,
HPLC and HPTLC methods are considered to be most suitable. Since these are powerful and
rudgged methods and also extremely precise, accurate, sensitive, specific, linear and rapid.
              The drugs analysis plays  an important  role  in the development of drugs,  their
manufacture  and  therapeutic  use.Pharamaceutical  industries  rely  upon  quqntitive  chemical
analysis to ensure that the raw material used and  the final product obtained meets the required
specification.The number of drugs and drug formulations introduced into the market has beeb
increasing at an alarmiing rate. These drugs or formulations may be either new entities in the
market or partial structural modification of the existing drugs or novel dosage forms or multi
component dosage forms.
 The multi  component dosage forms proved to be effective due to combined mode of
action on the body.The complecity of including the precense of multiple drug entities posses
considerable challenge to the analytical chemist during the development of assay procedure.The
estimationof individual drugs in these multi component dosage forms becomes difficult due to
some extraction or isolation procedures.
             For the present study ofloxacin and ornidazole was selected. The extensive literature
survey carried out revealed that there is no method reported for the simultaneous estimation of
these drugs, some mathods for estimation of combined drugs by HPLC and spectrophotametry
are available.Hence present study aim to developing a specific, precise, accuracy, linear, simple,
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rapid,  validated and cost  effetive RP-HLPC method for  the simultaneous estimation of these
drugs in copmbined dosage forms.
The core of project for RP-HLPC amaethod was designed as follows:
1. Selection of suitable wavelength,
2. Selection of stationary phase and mobile phase,
3. Selection of initial separation conditions,
4. Optimization of chromatrophic conditions,
5. Estimation of ofloxacin and ornidazole
6. Method validation.
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MATERIALS AND METHODS
MATERIALS USED FOR METHOD DEVELOPMENT AND VALIDATION
INSTRUMENT USED:
HPLC  : Equipped with a UV detector capable of 
operating in the range of 200 -400 nm 
Shimadzu. (Software Autochrome 3000) 
pH Meter                         : Range from 0  -14.Deep vision
Analytical balance          : Accurate to 0.001g- Shimadzu
Solvent filteration Unit  : Milli pore –Rankem
Syringe filters                : Nylon 0.22µ filter, PVDF 0.45 µ filters
Centrifuge                     : Remi
Sonicator                       : PCI Analytical labs
APPARATUS USED:
Graduated cylinder         : 50ml, 100, and 1000ml – Borosil.
Volumetric flask            : 200ml, 100ml, 50ml –Borosil.
Volumetric pipettes       : 10ml, 5ml, 30ml, 25ml, 20ml –Borosil.
Graduate pipettes           : 5ml, 10ml, 1ml, 2ml –Borosil
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Shimadzu HPLC –Model –LC 10ATvp
Specification
Column Cosmosil C18 MS –II Packed column(150mm x 4.6mm,5µm)
Pump LC 10AT vp
Detector UV
Temperature Ambient 
Chemicals Used:
Potassium dihydrogen ortho Phosphate        : Ranbaxy
Ortho phosphoric acid                                  : S.D fine Chem
Water                                                             : Milli Q (Ranbaxy)
Acetonitrile                                                    : Merck HPLC grade
Software Used                                               : Auto chrome 3000
Standard Used                                               
Ofloxacin Working Standard of Known potency
Ornidazole Working Standard of Known Potency
Source of drugs:
 Samples were collected from   Viencee pharma science.
METHOD DEVELOPMENT
Determination of λ max
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Weighed  and  transferred about 100mg of ofloxacin  working standard  into a
100ml  volumetric   flask,  added  about  60ml  of  mobile  phase   and  sonicated   to
dissolve  and dilute to volume  with mobile phase and mixed.
Transfer 1.0ml of the above solution into a 100ml volumetric flask, diluted to volume
with mobile phase and mixed.
Weighed  and  transferred about 100mg of  Ornidazole  working standard  into
a 100ml volumetric   flask,  added about 60ml of  mobile  phase  and sonicated  to
dissolve  and dilute to volume  with  mobile phase and mixed.
Transfer 1.0ml of the above solution into a 100ml volumetric flask, diluted to volume
with mobile phase and mixed.
Above solution scanned in the range of 200nm to 400nm
Observation:
               The  two absorbance graph overlain  spectra it was found  that the  two drugs
have marked absorbance  at 308 nm and   can be effectively  used for estimation  of
two  drugs without interference.(Figure:6)  
Conclusion:
Interest of wave length concluded as 308nm 
The objective of this experiment was to optimize the assay method for estimation of
ofloxacin and Ornidazole based on the literature survey and the trails made. The trials
mentioned below describes how the optimization was done.
 Trial-1:
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Buffer preparation  : Weigh accurately 0.2721gms of potassium 
dihydrogen Orthophosphate and dissolve it in 
1000ml of HPLC water.  Filter through 0.45µm
membrane filters and degas.
Mobile Phase   :  Buffer and acetonitrile were mixed in the ratio 
of 70:30 and Sonicated to degas filter 0.45 µm
membrane filters.
Diluents  :     Mobile phase   
Chromatographic condition   :
Column :  CosmosilC18 –MS-II column (150 x 4.6mm, 
5µm     Particle size) 
Column Temperature     : Ambient
Flow rate                        : 1.0ml/min
Injection volume    : 20µl
Detector wave length  : 308nm
Run time    : 10 min
Conclusion                 :  The peak was observed but the plate count   for 
Ofloxacin is below 2000. (Figure:7)
Trial 2:
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Buffer preparation : Weigh accurately 0.2721gms of potassium 
Dihydrogen Orthophosphate and dissolve it in 
1000ml of  HPLC water.  Adjust  the  pH to 3.5
with dilute ortho phosphoric acid solution filter
through 0.45µm membrane filters and degas. 
Mobile phase       :  Buffer and acetonitrile were mixed in the ratio 
of 70:30  and   sonicated to degas filter 
0.45 µm membrane filters.
Diluents :     Mobile phase   
Chromatographic conditions:
Column                            : CosmosilC18 –MS-II column (150 x 4.6mm, 
5µm particle size)
Column Temperature       : Ambient
Flow rate                           : 1.0ml/min
Injection volume               : 20µl
Detector wave length       : 308nm
Run time                          : 10 min
Conclusion                  :  The peak was observed but the plate count   for 
Ofloxacin and ornidazole is below 2000. 
(Figure: 8)
Trial 3:
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Buffer preparation   :       Weigh accurately 0.2721gms of Potassium 
dihydrogen   orthophosphate and dissolve it in
1000ml of  HPLC water.  Adjust  the  pH to 3.0
with dilute ortho phosphoric acid solution filter
through 0.45µm membrane filters and degas.
 Mobile phase : Buffer and acetonitrile were mixed in the ratio 
of 70:30 and sonicated to degas filter 0.45 µm
membrane filters.
Diluents                         :     Mobile phase   
Chromatographic conditions :
Column                       :  CosmosilC18 –MS-II column (150 x 4.6mm, 
5µm particle size)
Column Temperature       : Ambient
Flow rate                          : 1.0ml/min
Injection volume   : 20µl
Detector wave length     : 308nm
Run time                         : 10 min
Conclusion                     :  The peak was observed but the plate count   for 
Ofloxacin is below 2000. (Figure: 9) 
Trial 4:
Buffer Preparation                :   Weigh accurately 2.721gms of potassium 
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dihydrogen  Orthophosphate  and  dissolve  it  in
1000ml of  HPLC water.  Adjust  the  pH to 3.0
with dilute orthophosphoric acid solution    filter
through 0.45µm membrane filters and degas. 
Mobile phase : Buffer and acetonitrile were mixed in the ratio 
Of  70:30    and   sonicated to degas filter 0.45 
µm membrane filters.
Diluents                             :          Mobile phase   
Chromatographic conditions:
Column                       :  CosmosilC18 –MS-II column (150 x 4.6mm, 
5µm particle size)
Column Temperature     : Ambient
Flow rate                        : 1.0ml/min
Injection volume            : 20µl
Detector wave length     : 308nm
Run time                         : 10 min
Conclusion                     :  The peak was observed but the plate count   for 
ofloxacin is below 2000. (Figure:10)10
Trial 5: 
Buffer preparation                  : Weigh accurately 2.721gms of potassium 
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dihydrogen  Orthophosphate  and  dissolve  it  in
1000ml of  HPLC water.  Adjust  the  pH to 3.0
with dilute orthophosphoric acid solution    filter
through 0.45µm membrane filters and degas
Mobile phase : Buffer and acetonitrile were mixed in the ratio
of 80:20 and   sonicated to degas filter 0.45 µm
membrane filters.
Diluents           :         Mobile phase
Chromatographic conditions:
Column                          :  CosmosilC18 – MS-II column (150 x 
4.6mm,5µm particle size)
Column Temperature    : Ambient
Flow rate                      : 1.0ml/min
Injection volume          : 20µl
Detector wave length   : 308nm
Run time                       : 10 min
Conclusion :  The peak was observed with good tailing and 
good shape, with plate count for ofloxacin and
ornidazole  2236,  8794  and  tailing  factor  1.7
&1.3 and this Method was finalized for assay of
ofloxacin and ornidazole tablets. (Figure: 11)
Preparation of standard solution:
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Weigh and transfer accurately about  100.8mg of ofloxacin  working standard  and
250 .2mg of ornidazole  working standard into a 100ml volumetric flask, add about
60ml of mobile phase   and sonicated to dissolve and dilute to volume with mobile
phase  and mix.(Stock solution-I)
 Transfer 10ml of the above (stock solution-I) into a 100 volumetric flask and dilute to
volume with mobile phase and mix. (Stock solution -II)
Transfer 30ml of the above (stock solution-II) into a 100 volumetric flask and dilute
to volume with mobile phase and mix. (Stock solution -III)
Preparation of sample solution:
Accurately weigh and transfer tablet content to about 508.2mg of sample into a 100ml
volumetric flask, add about 60ml of mobile phase and sonicate for 30 minutes and
make up to 100ml with mobile phase. (Stock solution-I)
Transfer 10ml of the above solution (Stock solution-I) into a 100 volumetric flask and
Dilute to volume with mobile phase and mix. (Stock solution -II)
Transfer 30ml of the above solution (stock solution-II) into a 100 volumetric flask and
Dilute to volume with mobile phase and mix. (Stock solution -III) 
Procedure:
     Equilibrate  the column  with mobile phase  for  not less than  30 minutes  at  a
flow  rate of 1.0ml/min. Separately inject 20µl of diluents as  blank standard solution
(six  times  )  and   sample  solution  into  the  chromatographic  system.  Record  the
chromatograms and measure the peak responses.
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 System suitability: The column efficiency as determined for the ofloxacin and 
ornidazole peak from standard solution is NLT 2000 theoretical plates.
Tailing   factor   for  ofloxacin  and  ornidazole   peak   obtained  from  standard
chromatogram should be NMT 2.0 The % RSD  for  the ofloxacin and ornidazole
peak for 6replicate  injections of standard  solution should be  NMT 2
The retention time of  ofloxacin peak is  about 3.0 minutes and ornidazole peak is
about 6.0minutes 
Calculations:
Quantity of ofloxacin and ornidazole present in the tablet as % of labeled amount:
        =                AT   x  Ws  x    10   x  30   x 100  x100   x  100 x P  x   T x    100
                          -------------------------------------------------------------------------------
                          AsT  x 100  x   100  x   100 xWT   x 10  x30   x 100  x  L
AT: - Area of ofloxacin peak   in sample solution
AT: - Area of ornidazole peak   in sample solution
As: - Average area of ofloxacin peak obtained from six replicate injections of standard
solution.
As: -  Average area of  Ornidazole   peak obtained from six replicate injections of
standard solution.
 P: - Purity of ofloxacin working standard used
P: - Purity of ornidazole working standard used
WT: - Weight of sample taken, in mg
Ws: - Weight of ofloxacin working standard taken, in mg
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Ws: - Weight of ornidazole working standard taken,in mg
L: - Labeled amount of ofloxacin, in mg per tablet
L: - Labeled amount of ornidazole, in mg per tablet
T: - Average fill weight of tablet in mg.
Dept. of Pharmaceutical Analysis            68           JKKMMRF College of Pharmacy
Chapter – 5                                                                                Materials and Methods
METHOD VALIDATION
1. System  suitability  and  system  precision
A  standard  solution  was  prepared  by  using  ofloxacin  and  ornidazole  working
Standards as per test method and was injected six times into the HPLC system. 
The system suitability parameters were evaluated from standard chromatograms by
calculating  the  % RSD from six  replicate  injections  for  ofloxacin  and ornidazole
retention   times and peak areas.
Acceptance criteria:
1. The % RSD for the retention times of principal peak from six replicate
injections of each standard solution should be not more than 1.0 and for
peak area should not be More than 2.0.
2. The number of theoretical plates (N) for the ofloxacin peak and ornidazole 
peak is NLT 2000. 
3. Tailing factor (T) for the ofloxacin peak and ornidazole peak is NMT 2.0
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Table: 1 system suitability for ofloxacin
Injection Retention time Peak Area USP plate count USP Tailing
1 3.0 1105 2696 1.8
2 3.0 1108 2687 1.8
3 3.0 1108 2522 1.8
4 3.0 1106 2189 1.7
5 3.0 1104 2539 1.8
6 3.0 1112 2494 1.8
Mean 3.0 1107 2521 1.78
SD 2.60
% RSD 0.24
Observation:
The %RSD for retention times and peak areas were found to be within the limits.
(Figure: 12-17) 1212((
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Table: 2 system suitability for ornidazole
Injection Retention time Peak Area USP plate count USP Tailing
1 6.0 1810 7453 1.3
2 6.0 1815 7460 1.3
3 6.0 1804 7511 1.3
4 6.0 1819 7531 1.3
5 6.0 1813 7495 1.3
6 6.0 1792 7501 1.3
Mean 6.0 1809 7492          1.3
SD                                        8.82
% RSD                                        0.49
Observation:
The %RSD for retention times and peak areas were found to be within the limits.
(Figure: 13-18)
Accuracy: (Recovery)      A study of  accuracy was  conducted.  Drug assay was
performed in triplicate as per test  method by spiking the ofloxacin and ornidazole
drug substance to the placebo equivalent to 50%, 100%, and 150% of the labeled
amount as per the test method. The average % recovery of ofloxacin and ornidazole
was calculated.
Separately  inject  the  blank,  placebo,  ofloxacin  and  ornidazole  in  to  the
chromatograph. 
Acceptance criteria:
The mean % recovery of ofloxacin and ornidazole at each level should be not less
than 98.0 % and not more than 102.0% 
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Table: 3 Accuracy for ofloxacin
Concentration  
% of spiked 
level
Amount 
added (in mg 
as ofloxacin)
Amount 
found (in 
mg as 
ofloxacin)
% 
Recovery 
Statistical analysis
of % Recovery
50% Sample 1 100.7 99.3 98.6 MEAN 99.1
50% Sample 2 100.8 100.3 99.5 SD 0.37
50% Sample 3 101.3 100.5 99.2 %RSD 0.38
100% Sample 1 200.7 198.9 98.2 MEAN 98.9
100% Sample 2 200.8 199.7 98.9 SD 0.53
100% Sample 3 200.3 199.8 99.5 %RSD 0.54
150% Sample 1 300.5 299.8 99.3 MEAN 99.1
150% Sample 2 300.7 299.9 98.5 SD 0.43
150% Sample 3 301.4 300.9 99.5 %RSD 0.44
Observation: The recovery results indicating that the test method has an acceptable
level of accuracy. (Figure: 19-27)
Table: 4 Accuracy for ornidazole
Concentration  
% of spiked 
level
Amount 
added (in mg 
as 
ornidazole )
Amount 
found (in 
mg as 
ornidazole)
% 
Recovery 
Statistical analysis
of % Recovery
50% Sample 1 250.8 249.2 98.4 MEAN 98.7
50% Sample 2 248.5 247.7 99.2 SD 0.38
50% Sample 3 250.7 249.1 98.4 %RSD 0.38
100% Sample 1 500.5 499.4 98.9 MEAN 98.5
100% Sample 2 500.2 498.3 98.1 SD 0.33
100% Sample 3 499.4 498.0 98.6 %RSD 0.33
150% Sample 1 750.4 749.1 98.8 MEAN 98.8
150% Sample 2 749.6 749.1 99.5 SD 0.54
150% Sample 3 750.2 748.4 98.2 %RSD 0.54
Observation: The recovery results indicating that the test method has an acceptable
level of accuracy. (Figure: 19-27)
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3. Precision:
a. System  precision:  standard  solution  was  prepared  as  per  test  method  and
injected Six times in to chromatographic system.
b. Method precision: prepared six sample solutions of 100mg strength as per test 
Method and injected each solution into chromatographic system. 
Acceptance criteria:
1. % RSD of   % assay results from six samples should be NMT 2.0
2. Assay should  be in the range of test method  i.e. .not less than 90.0% and  
not more than 110.0% 
a)System precision:
                                          Table: 5 system precision for ofloxacin 
Injection Peak Areas Theoretical plates Tailing  factor
1 1077 2962 1.7
2 1095 2478 1.6
3 1096 2878 1.6
4 1088 2460 1.7
5 1086 2923 1.6
6 1093 2495 1.7
Mean 1089 2699 1.65
SD        6.51
%RSD      0.60
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Table: 6 system precision for ornidazole
Concentration 
100%
Injection Peak Areas Theoretical plates Tailing  
factor
1 1767 8028 1.2
2 1770 8035 1.2
3 1792 9374 1.3
4 1781 9444 1.2
5 1785 7971 1.3
6 1822 9148 1.2
Statistical  
analysis
Mean 1786 8667 1.23
SD 18.14
%RSD 1.02
b) Method precision:
Table: 7 Method precision for ofloxacin
Sample 
No.
Injection 
No.
Area Average 
Area
% Assay
1 1 1144 1134 100.9
2 1124
2 1 1127 1136 100.7
2 1145
3 1 1135 1137 100.4
2 1138
Mean 100.7
Standard deviation 0.21
%RSD 0.20
Table: 8 Method precision for Ornidazole
Dept. of Pharmaceutical Analysis            74           JKKMMRF College of Pharmacy
Chapter – 5                                                                                Materials and Methods
Sam
ple 
No.
Injectio
n 
No.
Area Average 
Area
% Assay
1 1 1807 1799 99.8
2 1790
2 1 1794 1791 99.4
2 1787
3 1 1796 1800 99.6
2 1803
Mean 99.6
Standard deviation 0.16
%RSD 0.16
Observation: The precision study has shown that the test method is precise. (Figure
34- 39) 
4. Linearity of test method:
Five linearity solutions were  prepared using ofloxacin and ornidazole  working
standard at concentration levels from 50% to 150% of  target concentration  of
ofloxacin  and ornidazole (50%,75%,100%,125% and  150%) .Measure the peak
area response of solution at level 1and level 5 three times.
Acceptance criteria:
 Correlation coefficient should be not less than 0.999.
% of y- intercept should be + 2.0
% of RSD for level 1 and level 5 should be not more than 2.0
                          
Table: 9 Linearity   for ofloxacin
Linearity Concentration Average Area %RSD Statistical Analysis
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Level ppm
L1-50% 10ppm 372 0.46 Slope 0.01
L2-75% 20ppm 744 0.23 %intercept -1.19
L3-100% 30ppm 1108 0.26 Correlation 
Coefficient 
0.9998
L4-125% 40ppm 1456 0.12
L5-150% 50ppm 1824 0.16
Observation:
 
The correlation coefficient was found to be 0.9998 
From the above study it was established that the linearity of test method is from 50% 
to 150% of the target concentration. (Figure: 40-54)                    
Table: 10 Linearity   for ornidazole
Linearity 
Level
Concentration 
ppm
Average 
Area
%RSD Statistical Analysis
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L1-50% 25ppm 612 0.46 Slope 0.01
L2-75% 50ppm 1220 0.22 %intercept -0.98
L3-100% 75ppm 1806 0.55 Correlation 
Coefficient 
0.9999
L4-125% 100ppm 2388 0.14
L5-150% 125ppm 3000 0.06
Observation:
 
The correlation coefficient was found to be 0.9999
From the above study it was established that the linearity of test method is from 50% 
to 150% of the target concentration. (Figure: 40-54)
4. Range:
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Data from linearity, precision, accuracy, sections was considered to establish range of 
the method. The results were summarized in table 24
Acceptance criteria:
For linearity, Correlation coefficient shall be ≥0.999.
For precision, %RSD of assay of 3 replicate sample preparations shall be NMT 2.0%.
For accuracy, individual recovery at each spike level should be within 98.0% to 102%
Table: 11 Range for ofloxacin
Parameter Acceptance criteria Result
Linearity R≥0.999 0.9998
Precision %RSD of 3 replicates NMT 2.0                 0.20
Accuracy Recovery 98.0% to  102.0%                 99.03
Table: 12 Range for Ornidazole
Parameter Acceptance criteria Result
Linearity R≥0.999 0.9999
Precision %RSD of 3 replicates NMT 2.0                  0.16
Accuracy Recovery 98.0% to  102.0%                  98.67
5. Selectivity /Specificity:
Placebo interference:
          A study to establish the interference of placebo was conducted. Samples were 
prepared in triplicate by taking the placebo equivalent to about the weight in portion 
of test preparation as per the test method.
Acceptance criteria:
The chromatogram of placebo should not show any peak at the retention time of 
ofloxacin and ornidazole.
Table: 13 placebo interference 
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Ofloxacin Ornidazole Peak found
                    1                     1 No
                    2                     2 No
                    3                     3 No
Observation:  From placebo  chromatograms,  it  was  concluded  that  there  was  no
interference  with  placebo  as  no  peaks  were  observed  at  the  retention  times  of
ofloxacin and ornidazole peaks. 
6. Limit of detection and limit of quantification:
Procedure:
The  quantitation  limit  of  an  individual  analytical  procedure  is  the  lowest
amount of analyte in a sample that can be determined quantitatively with suitable
precision and accuracy. The detection limit of an individual analytical procedure is the
lowest  amount  of  analyte  in  a  sample  that  can  be  detected  but  not  necessarily
quantities as an exact Value.
           As per linearity curve, we have prepared 1 ppm for detection of ofloxacin and
ornidazole, 3ppm for quantitation for ofloxacin and ornidazole. Determine the signal
noise ratio about 3.Determine the ratio at analyte concentration  of 0.001%.If signal
noise is 10 or more, quality this concentration  as limit of quantification  .if signal
noise ratio is less than 10,increase  the   concentration  but  not beyond 0.003%,to
achieve the signal to noise  ratio 10 and then  qualify the  concentration as limit of
quantification.
7. Ruggedness of the test method: 
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System to system /Analyst to analyst /column to column variability:
        System to system /analyst to analyst /column to column variability study was
conducted on different HPLC system, different columns and different analysts under
similar  conditions  at  different  times.  Six  samples  were  prepared  and  each  were
analyzed  as  per  test  method.  The  relative  standard  deviation  for  ofloxacin  and
ornidazole was found to be below 2% on the columns, system and analysts. 
Comparison of both the results obtained on two different HPLC systems, different
column and different analysts shows that the assay test method is rugged for system to
system /analyst to analyst/column to column variability.
Acceptance criteria:
The % RSD   of ofloxacin   and ornidazole from the six sample preparations should be
not more than 2%
                                             Table – 14 Ruggedness for ofloxacin 
S.No Concentration  for 30ppm Average area of six 
samples
%RSD
1 Analyst -1 1089 0.60
2 Analyst -2 1107 0.24
                                            Table – 15 Ruggedness for ornidazole 
S.No Concentration  for 75 
ppm
Average area of six 
samples
%RSD
1 Analyst -1 1789 1.02
2 Analyst -2 1809 0.49
Observation: The % RSD   was found within the limits.
8. Robustness:
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i) Filter variability: (At least two filters). 
       For demonstrating that the filtration does not affect the analysis results. At least
two types of filters were validated before use. Prepare the standard solution as per test
method. Filter the standard solution through individual filter .PVDF and nylon filter
were used. Inject unfiltered standard solution and filtered standard solution into the
HPLC system under the test condition. 
Calculate the average area of duplicate injections of individual standard solutions and
determine similarity factor of filtered standard solution against unfiltered standard.
Similarity factor =    A/B
Where, A: Average area of filtered standard           
  B: Average area of unfiltered standard
Acceptance criteria:
The similarity factor of test solution against unfiltered standard solution should be in 
the range of 0.98   to 1.02.
Table: 16 Filter validations for ofloxacin
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S.No Preparation of 
sample
 ( ofloxacin)
Standard area Sample area Average Similarity
Factor
1
By centrifugation
1089
1086
           0.9892 1068
1
By 0.45µ PVDF  
Filter
1070
0.9902 1087
1
By Nylon  0.22 µ 
Filter
1075
0.9892 1078
Table: 17 Filter validations for ornidazole
S.No Preparation of 
sample
 ( ofloxacin)
Standard Area Sample Area Average Similarity
Factor
1
By centrifugation
1786
1789
0.996
2 1768
1
By 0.45µ PVDF  
Filter
1718
0.990
2 1712
1
By Nylon  0.22 µ 
Filter
1734 0.992
2 1715
  
Observation: The similarity factor was found to be within the limits.
ii) Effect of variation in mobile phase composition:
     A study was conducted to determine the effect  of  variation in organic phase
composition in mobile phase. Standard solution prepared as per the test method was
injected into the HPLC system with 90% and 110% of organic phase with respect to
test method. The system suitability parameters were evaluated and found to be within
the  limits  for  both compositions.  Ofloxacin and ornidazole was resolved  from all
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other peaks and the retention times were comparable with those   obtained for mobile
phase having 100% of the organic phase.   From the study it was established that the
allowable variation in mobile phase   Composition is 90% to 110% of the method
highest organic phase of mobile phase.
Acceptance criteria:
    The Tailing factor for ofloxacin and ornidazole standards should be NMT 2.0 for 
variation in organic phase 
Table: 18 Effect of variable in mobile phase composition
S.No Mobile phase composition
(buffer:ACN)
Area of 
ofloxacin 
%RSD of peak area Tailing 
factor
1. 87:13 1075 0.93 1.3
2. 85:15 1103 0.36 1.4
3. 83:17 1131 0.40 1.5
Table: 19 Effect of variable in mobile phase composition
S.No Mobile phase 
composition
(buffer:ACN)
Area of 
ornidazole 
%RSD of peak area Tailing factor
1. 87:13 1735 0.58 1.0
2. 85:15 1758 0.20 1.1
3. 83:17 1771 0.11 1.2
Observation:
The tailing factor for ofloxacin and ornidazole is found to be within the limits
   iii)   Effect of variation of flow rate   :
A study was conducted to determine the effect of variation   in flow rate. 
standard solution prepared as per the test method was injected into the HPLC system 
using flow rates, 0.9ml/min and 1.1ml/min.The system suitability parameters were 
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evaluated and found to be within the limits for 0.9ml/min and 1.1ml/min flow. 
ofloxacin and ornidazole was resolved from all other peaks and retention time were  
comparable with those obtained for mobile phase flow rate 1.0ml/min.
from the above study it was established that the allowable variation in flow rates is 
0.9ml/min and 1.1ml/ml.
Acceptance criteria:                                    
      The tailing factor of ofloxacin and ornidazole standards should be NMT 2.0 for 
variation in flow.
                                      Table -20 Effect of variation in flow rate
S.No Flow rate Area of
ofloxacin
%RSD of the peak
area
Tailing factor
1 0.9ml/min 1208 0.21 1.7
2 1.0ml/min 1089 0.60 1.7
3 1.1ml/min 970 0.52 1.7
                                  Table -21 Effect of variation in flow rate
S.No Flow rate Area of
ornidazole
%RSD of the peak
area
Tailing factor
1 0.9ml/min 1987 0.60   1.3
2 1.0ml/min 1786 1.02 1.2
3 1.1ml/min 1628 0.15 1.2
Observation:
The tailing factor for ofloxacin and ornidazole is found to be within the limits. 
iv) Effect of variation of pH:
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A study was  conducted  to  determine  the  effect  of  variation  in  pH.  Standard  and
sample  solutions were prepared  as per the test method  and inject  into the HPLC
system  using pH 2.8  and 3.2 .The system suitability parameters were evaluated and
found to be within the limits for pH 2.8  and 3.2
Ofloxacin was resolved from all other peaks and the retention times were comparable 
with those obtained for mobile phase having pH 3.0. 
From the above study it was established that the allowable variation in pH 2.8 and 3.2
Acceptance criteria: 
The tailing factor of ofloxacin and ornidazole standard should be NMT 2.0 for 
variation in pH.
Table -22 Effect of pH
S.No pH Area of ofloxacin   %RSD of peak area Tailing factor
1 2.8 1078 0.74 1.4
2 3.0 1089 0.60 1.7
3 3.2 1070 0.51 1.5
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Table -23 Effect of pH
S.No pH Area of 
ornidazole
  %RSD of peak area Tailing factor
1 2.8 1760                  0.43 1.2
2 3.0 1786 1.02 1.2
3 3.2 1810 0.44 1.2
Observation:
The tailing factor for ofloxacin and ornidazole is found to be within the limits.
Conclusion:
From the above results it is concluded that the method is robust.
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CHROMATOGRAMS
UV Spectrum:
Sample Spectrum: 
Figure: 6
Method development trails in HPLC
Trial No.1
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.1 3981 1333 1.6
2 ornidazole 6.1 4980 2110 1.7
Figure: 7
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Trial No.2
                                                    
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.1 496 1314 1.4
2 ornidazole 6.1 629 1838 1.7
Figure: 8
Trial No.3
Name RT Area USP plate count USP Tailing
1 ofloxacin 2.5 377 1845 1.5
2 ornidazole 5.0 492 3359 1.9
Figure: 9
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Trial No.4
                                                              
Name RT Area USP plate count USP Tailing
1 ofloxacin 1.9 485 1365 2.0
2 ornidazole 3.3 603 4358 1.6
Figure: 10
Trial No.5
                                          
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.0 429 2236 1.7
2 ornidazole 6.1 572 8794 1.3
Figure: 11
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Mobile phase Blank
Name RT Area %Area
1 ofloxacin 3.0
2 ornidazole 6.0
Figure: 12
System suitability:
Injection: 1
                                                   
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.0 1105 2696 1.8
2 ornidazole 6.0 1810 7453 1.3
Figure: 13
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Injection: 2
                                                    
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.0 1108 2687 1.8
2 ornidazole 6.0 1815 7460 1.3
Figure: 14
Injection: 3
                                               
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.0 1108 2522 1.8
2 ornidazole 6.0 1804 7511 1.3
Figure: 15
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Injection: 4
                                                  
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.0 1106 2189 1.7
2 ornidazole 6.0 1804 7531 1.3
Figure: 16
Injection: 5
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.0 1104 2539 1.8
2 ornidazole 6.0 1813 7495 1.3
Figure:17
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Injection: 6
  
Figure:18
Accuracy  Chromatogram
50% sample-I
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Name RT Area USP plate count USP Tailing
1 ofloxacin 3.0 1112 2494 1.8
2 ornidazole 6.0 1792 7501 1.3
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Name RT Area
1 ofloxacin 3.3 367
2 ornidazole 6.5 608
Figure: 19
50% Sample-II
                                              
Name RT Area
1 ofloxacin 3.3 370
2 ornidazole 6.5 610
Figure:20
50% Sample-III
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Name RT Area
1 ofloxacin 3.3 369
2 ornidazole 6.4 608
Figure:21
100% Sample-I
                                            
Name RT Area
1 ofloxacin 3.3 1098
2 ornidazole 6.4 1802
Figure:22
100% Sample-II
Dept.of Pharmaceutical Analysis           95           JKKMMRF College of Pharmacy
Chapter – 6                                                                                           Chromatograms
                                                             
Name RT Area
1 ofloxacin 3.3 1102
2 ornidazole 6.4 1799
Figure:23
100% Sample-III
                                        
Name RT Area
1 ofloxacin 3.3 1105
2 ornidazole 6.4 1819
Figure:24
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150% Sample-1
                                     
Name RT Area
1 ofloxacin 3.3 1820
2 ornidazole 6.4 2995
Figure: 25
150%Sample-II
           
                                       
Name RT Area
1 ofloxacin 3.3 1816
2 ornidazole 6.4 2998
Figure: 26
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150%Sample-III
                                          
Name RT Area
1 ofloxacin 3.3 1821
2 ornidazole 6.4 2993
Figure: 27
System Precision Chromatograms
Injection-1
                                                      
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.3 1077 2962 1.7
2 ornidazole 6.4 1767 8028 1.2
Figure: 28
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Injection-2
                                                      
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.3 1095 2438 1.6
2 ornidazole 6.4 1770 8035 1.2
Figure: 29
Injection-3
                                                      
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.3 1096 2878 1.6
2 ornidazole 6.4 1792 9374 1.3
Figure: 30
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Injection-4
                                                      
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.3 1088 2460 1.7
2 ornidazole 6.4 1781 9444 1.2
Figure:31
Injection-5
                                                      
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.3 1086 2923 1.6
2 ornidazole 6.4 1785 7971 1.3
Figure: 32
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Injection-6
                                                      
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.4 1093 2495 1.7
2 ornidazole 6.4 1822 9148 1.2
Figure: 33
Method precision Chromatograms
Sample-1:
           
                                       
Name RT Area
1 ofloxacin 3.5 1144
2 ornidazole 6.8 1807
Figure:34
Dept.of Pharmaceutical Analysis           101           JKKMMRF College of Pharmacy
Chapter – 6                                                                                           Chromatograms
Sample-2:
            
                                       
Name RT Area
1 ofloxacin 3.5 1124
2 ornidazole 6.8 1790
Figure: 35
Sample-3:
           
                                       
Name RT Area
1 ofloxacin 3.5 1127
2 ornidazole 6.9 1794
Figure:36
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Sample-4:
           
                                       
Name RT Area
1 ofloxacin 3.6 1145
2 ornidazole 6.9 1787
Figure:37
           
                                       
Name RT Area
1 ofloxacin 3.6 1135
2 ornidazole 6.9 1796
Figure: 38
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Sample 6:
           
                                       
Name RT Area
1 ofloxacin 3.6 1138
2 ornidazole 6.9 1803
Figure: 39
Linearity chromatograms:
LI-50%-1:
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Name RT Area
1 ofloxacin 3.0 370
2 ornidazole 6.0 608
Figure: 40
LI-50%-2:
           
                                       
Name RT Area
1 ofloxacin 3.0 373
2 ornidazole 6.0 614
Figure: 41
LI-50%-3:
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Name RT Area
1 ofloxacin 3.0 374
2 ornidazole 6.0 614
Figure: 42
LI-75%-1:
           
                                       
Name RT Area
1 ofloxacin 3.0 746
2 ornidazole 6.0 1218
Figure: 43
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LI-75%-2:
                                                               
           
                                         
Name RT Area
1 ofloxacin 3.0 743
2 ornidazole 6.0 1224
Figure: 44
LI-75%-3:
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Name RT Area
1 ofloxacin 3.0 742
2 ornidazole 6.0 1219
Figure: 45
LI-100%-1:
                                                               
           
Name RT Area
1 ofloxacin 3.0 1112
2 ornidazole 6.0 1792
Figure: 46
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LI-100%-2:
                                                               
           
Name RT Area
1 ofloxacin 3.0 1105
2 ornidazole 6.0 1810
Figure: 47
LI-100%-3:
           
                                       
Name RT Area
1 ofloxacin 3.0 1108
2 ornidazole 6.0 1815
Figure: 48
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LI-125%-1:
           
                                       
Name RT Area
1 ofloxacin 3.0 1458
2 ornidazole 6.0 2387
Figure: 49
LI-125%-2:
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Name RT Area
1 ofloxacin 3.0 1454
2 ornidazole 6.0 2384
Figure:50
LI-125-3:
           
                                        
Name RT Area
1 ofloxacin 3.0 1455
2 ornidazole 6.0 2392
Figure: 51
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LI-150%-1:
                                                              
         
Name RT Area
1 ofloxacin 3.0 1823
2 ornidazole 6.0 3002
Figure: 52
LI-150%-2:
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Name RT Area
1 ofloxacin 3.0 1821
2 ornidazole 6.0 2999
Figure: 53
LI-150%-3:
           
                                       
Name RT Area
1 ofloxacin 3.0 1828
2 ornidazole 6.0 2998
Figure: 54
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Placebo interference chromatograms
Placebo-1
                                            
Name RT Area %Area
1 ofloxacin 3.0
2 ornidazole 6.0
Figure: 55
Placebo-2
                                            
Name RT Area %Area
1 ofloxacin 3.0
2 ornidazole 6.0
Figure: 56
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Placebo-3
                                            
Name RT Area %Area
1 ofloxacin 3.0
2 ornidazole 6.0
Figure: 57
Limit of detection chromatograms:
Injection -1
     
Name RT Area USP plate count USP Tailing
1 ofloxacin 2.9 42 2858 1.7
2 ornidazole 5.7 63 8205 1.2
Figure: 58
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Injection -2
     
                                                             
Name RT Area USP plate count USP Tailing
1 ofloxacin 2.9 43 3034 1.6
2 ornidazole 5.7 63 7125 1.3
Figure: 59
Limit of Quantification chromatograms
Injection -1
     
                                                        
Name RT Area USP plate count USP Tailing
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1 ofloxacin 2,9 112 2803 1.8
2 ornidazole 5.7 175 7807 1.2
Figure: 60
Injection -2
     
                                                             
Name RT Area USP plate count USP Tailing
1 ofloxacin 2.9 115 2876 1.7
2 ornidazole 5.7 181 7092 1.3
Figure: 61
Injection -3
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Name RT Area USP plate count USP Tailing
1 ofloxacin 2.9 116 2863 1.7
2 ornidazole 5.7 184 6923 1.2
Figure: 62
Injection -4
                                                    
                                                             
Name RT Area USP plate count USP Tailing
1 ofloxacin 2.9 117 2984 1.6
2 ornidazole 5.8 183 6951 1.3
Figure: 63
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Injection -5
     
                                                             
Name RT Area USP plate count USP Tailing
1 ofloxacin 2.9 115 2386 1.8
2 ornidazole 5.9 183 6960 1.3
Figure: 64
Injection -6
                                                    
                                                             
Name RT Area USP plate count USP Tailing
1 ofloxacin 3.0 117 2820 1.8
2 ornidazole 5.9 185 6902 1.2
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Figure: 65
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RESULT AND DISCUSSION
            A simple Reverse phase high performance liquid chromatographic  method has been developed and
subsequently validated for ofloxacin and ornidazole tablets.
           The separation was carried out by using a Buffer: Acetonitrile (80:20).The detection was carried out
at  308nm.The  column  was  Cosmosil  C18-MS-II  packed  column (150  x4.6mm ,5µ).the  flow rate  was
selected as 1ml/min.
         The retention time of ofloxacin  and ornidazole was found  to  be 3.0 and 6.0. The asymmetry factor or
tailing factor of ofloxacin and ornidazole was found to be 1.78 and 1.3, which indicates symmetrical nature
of the peak.  The number of theoretical  plates of  ofloxacin and ornidazole was found to be 2546 and
6578,which indicates the efficient  Performance of the column .These parameters represent the specificity of
the method.
          From the linearity studies, specified concentration levels were determined. it was observed that
ofloxacin and ornidazole  were linear in the range of 50% to 150% for the target concentration by RP-
HPLC.The linearity range of ofloxacin and ornidazole  50% to 150% was found to obey linearity with a
correlation coefficient   to  0.9998,and 0.9999. The validation of  the proposed method was verified  by
system precision  and method precision by RP-HPLC.The %RSD of system suitability for ofloxacin and
ornidazole  was found to be  0.24,0.49.
         The validation of the proposed method was verified by recovery studies. The percentage recovery
range  was  found  to  be  satisfied  which  represent  in  results.  The  robustness  studieswere  performed  by
changing the flow rate , filters and wavelength.The ruggedness study was also
performed.The analytical method validation was carried out by RP-HPLC as per ICH guidelines and given
below are the tables are the summary of the results.
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Analytical method validation report for ofloxacin and ornidazole tablets
Table -24
S.N
o
Parameter Experiment Observation Acceptance criteria
01 System suitability
System suitability
Ofloxacin 
0.24%
RSD NMT 2.0%
1.78
Tailing factor NMT 2.0
System suitability
Ornidazole
0.49%
RSD NMT 2.0%
1.3
Tailing factor NMT 2.0
02 Specificity Placebo 
interference
Placebo not 
shown any 
peak at the 
retention time 
of ofloxacin 
and 
ornidazole 
peak.
Placebo should not 
show any peak at the 
retention time  of 
ofloxacin and 
ornidazole peak
03 Limit of detection Ofloxacin 0.001mg/ml NMT 2
Ornidazole 0.0025mg/ml NMT 2
Limit of 
quantitation
Ofloxacin 0.003 mg/ml NMT 10
Ornidazole 0.0075mg/ml NMT 10
Dept.of Pharmaceutical Analysis         119             JKKMMRF College of Pharmacy
Chapter-7                                                                                     Result and
Discussion
S.No Parameter Experiment Observation Acceptance 
criteria
04 Linearity
Correlation 
coefficient for 
ofloxacin
0.9998 NLT 0.999
Correlation 
coefficient for 
Ornidazole
0.9999 NLT 0.999
05 Precision
Repeatability for 
ofloxacin 
0.60% %RSD NMT 
2.0%
Repeatability for 
ornidazole
1.02% %RSD NMT 
2.0%
Method precision
For ofloxacin 
0.21% %RSD NMT 
2.0%
100.7% Assay: 90 .0% to
110.0%
Method precision
For ornidazole
0.16% %RSD NMT 
2.0%
99.6% Assay:90 .0% to 
110.0%
06 Range 
Accuracy  for 
ofloxacin
Spike 
level
%Mean 
recovery
Mean recovery  
should be within 
98.0% to 102.0%
50% 99.1%
100% 98.9%
150% 99.1%
Accuracy  for 
ornidazole
50% 98.7%
100% 98.5%
150% 98.8%
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S.N
o
Parameter Experiment Observation Acceptance criteria
07 Ruggedness
Analyst-1
Ofloxacin :0.60%
Ornidazole:1.02%
Analyst-II
Ofloxacin :0.24%
Ornidazole:0.49%
%RSD NMT 2.0%
08 Robustness
Effect  of  
variation  in flow 
rate
System  
suitability 
Pass
System suitability
should passAllowable 
variation :
0.9  to  1.1 
ml/min
Effect of 
variation in 
composition of 
mobile phase
System
suitability
Pass System suitability
should passAllowable 
variation :90% to 
110% of the 
method highest 
organic phase
Filter validation This is no effect 
of filtered and 
centrifuged 
sample 
Similarity factor of
centrifuged against
filtered should be in
0.98% to 1.02%
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CONCLUSION
A RP-HPLC method for ofolaxacin and ornidazole were developed and validated in tablet
dosage  form as  per  ICH guidelines.  The results  are  found  to  be  complying with  the
acceptance criteria for each of the parameter.
Shimadzu HPLC(Autochrome 3000 software with UV detector) with Cosmosil C18 –MS
–II (150X 4.6MM, 5µ) Packed Column, Injection  volume of 20µl is injected and eluted
with  the Mobile phase ( Buffer  and CAN, in the ratio of 80:20) Which  was pumped at a
flow rate  of 1.0 ml at  308nm.The peak of  ofloxacin and ornidazole was found well
separated  at   3.0min  ,  6.0min.The  developed  method  was  validated  for  various
parameters  as  per  ICH guidelines  like system suitability,accuracy,precision,  linearity ,
specificity, limit of detection ,limit of quantitation ,ruggedness,robustness.
Hence it is concluded that the assay method is found to be valid in terms of reliability,
precision, accuracy and specificity and hence it is suitable for routine anaclysis as well as
for  stability analysis.
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